<SEC-DOCUMENT>0001140361-23-017671.txt : 20230411
<SEC-HEADER>0001140361-23-017671.hdr.sgml : 20230411
<ACCEPTANCE-DATETIME>20230411073017
ACCESSION NUMBER:		0001140361-23-017671
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230405
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230411
DATE AS OF CHANGE:		20230411

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eterna Therapeutics Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		23812370

	BUSINESS ADDRESS:	
		STREET 1:		1035 CAMBRIDGE STREET
		STREET 2:		SUITE 18A
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		10531 4S COMMONS DRIVE
		STREET 2:		SUITE 166-550
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Brooklyn ImmunoTherapeutics, Inc.
		DATE OF NAME CHANGE:	20210325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10050812_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:erna="http://eternatx.com/20230405" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_845a1b5c582048cfaf54e45d285a62c2" contextRef="c20230405to20230405" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_9c7814419fd64747a86a6140dd4930fd" contextRef="c20230405to20230405">0000748592</ix:nonNumeric><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_ed129a2447cf4c71853a413e4d87b1a8" contextRef="c20230405to20230405">NASDAQ</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="erna-20230405.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230405to20230405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-05</xbrli:startDate><xbrli:endDate>2023-04-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;"><a id="z_Hlk104309906"></a><a id="z_Hlk104320152"></a><span style="font-size: 14pt;">UNITED STATES</span></div>

    <div><span style="font-size: 14pt;"> </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: left;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_dc49a7fe870e439aa89f5e6043cf9080" contextRef="c20230405to20230405">8-K</ix:nonNumeric></div>

    <div style="text-align: left;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: left;"><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_5be4150dfe6b4b399f8b26deb6eb8347" contextRef="c20230405to20230405" format="ixt:date-monthname-day-year-en">April 5, 2023</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_595da8fc1f45425a8e04d042aeb6bc36" contextRef="c20230405to20230405">Eterna Therapeutics Inc.</ix:nonNumeric></span><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

    <div style="text-align: left;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_5b122887297b44ef99e96ce1e0eb7107" contextRef="c20230405to20230405" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_487d0a3cb3ec48baa5cde6f7d4eec1a6" contextRef="c20230405to20230405">001-11460</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33%; vertical-align: bottom; text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_5418c62b6e3147f791eab05719e427ef" contextRef="c20230405to20230405">31-1103425</ix:nonNumeric></span><br />
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_834d2d330f564880aed1413ad2d0df1b" contextRef="c20230405to20230405">1035 Cambridge Street,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_68c811f91eb346fe8cbc74c70de0b4fb" contextRef="c20230405to20230405">Suite 18A</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-style: normal;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_0e32e15a74b549fd8d77ed73d77055a0" contextRef="c20230405to20230405">Cambridge,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_46f679009b97445c9bd947dc76ea28a8" contextRef="c20230405to20230405">MA</ix:nonNumeric></div>
            </div>
          </td>

    <td style="width: 2%; vertical-align: bottom;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-style: italic;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_10b2fd630e714af6850d0aed953cd38d" contextRef="c20230405to20230405">02141</ix:nonNumeric></div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-size: 10pt;" rowspan="1">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Address of Principal Executive Offices)</div>
          </td>

    <td style="width: 2%; vertical-align: bottom;" rowspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;" rowspan="1">
            <div style="text-align: center; font-family: 'Times New Roman'; font-style: italic;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_bb166c6003164e25b01f2ca4a43a3c59" contextRef="c20230405to20230405">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_a2f8d9b1af68438a84266c356939c664" contextRef="c20230405to20230405">582-1199</ix:nonNumeric></span></div>

    <div><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
      provisions:</div>

    <div><br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_1b19edaaf3864c908445437d28a12821" contextRef="c20230405to20230405" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_cec4dfc13efa47dab49838b2214c8e99" contextRef="c20230405to20230405" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_9cd6242a89364e13ad94fc13472f4790" contextRef="c20230405to20230405" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Segoe UI Symbol', sans-serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_385842461e27493a8c52f5d1f1409675" contextRef="c20230405to20230405" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 41.3%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 0.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 18.76%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">Trading symbol</div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 36.98%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 8pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 41.3%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_f4805cc393924d0581d9b688175739f2" contextRef="c20230405to20230405">Common Stock, $0.005 par value</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 0.96%; vertical-align: middle;">&#160;</td>

    <td style="width: 18.76%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_1f2b3a467d1f4955a84d07043039e00e" contextRef="c20230405to20230405">ERNA</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 2%; vertical-align: middle;">&#160;</td>

    <td style="width: 36.98%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_ed129a2447cf4c71853a413e4d87b1a8">The Nasdaq Stock Market LLC</span><br />
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange
      Act of 1934:</div>

    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_ca77247a8a0544d4ae8e7e6c8526cf9b" contextRef="c20230405to20230405" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /> </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Entry into a Material Definitive Agreement.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div>
      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On April 5, 2023, Eterna Therapeutics Inc., a Delaware corporation (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Company</span></span>&#8221;), entered into a purchase agreement (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Purchase Agreement</span></span>&#8221;) and a registration rights agreement (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Registration Rights Agreement</span></span>&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Lincoln Park</span></span>&#8221;), pursuant to which Lincoln Park has
        committed to purchase up to $10.0 million of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Common Stock</span></span>&#8221;), subject to certain limitations and satisfaction
        of the conditions set forth in the Purchase Agreement.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement, the Company has the right,
        but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10.0 million of Common Stock. Such sales of Common Stock by the Company, if any, are subject to certain limitations set forth in the Purchase
        Agreement, and may occur from time to time, at the Company&#8217;s sole discretion, over a period of up to 24-months, commencing on the date on which each of the conditions to Lincoln Park&#8217;s purchase obligations set forth in the Purchase Agreement have
        initially been satisfied (such date, the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Commencement Date</span></span>&#8221;), including the effectiveness of a registration statement registering under the Securities Act of 1933, as
        amended (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Securities Act</span></span>&#8221;), the resale by Lincoln Park of shares of Common Stock that have been and may be issued by the Company to Lincoln Park under the Purchase
        Agreement.&#160; The Company has agreed to file such registration statement with the Securities and Exchange Commission (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">SEC</span></span>&#8221;) not later than 10 business days after the
        date of execution of the Purchase Agreement and the Registration Rights Agreement.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">From and after the Commencement Date, the Company may from time to time, on any business day selected by the Company on which the
        closing sale price per share of Common Stock as reported on The Nasdaq Capital Market is not less than the &#8220;floor price&#8221; threshold set forth in the Purchase Agreement (each such business day, a &#8220;purchase date&#8221;), by written notice delivered by the
        Company to Lincoln Park, direct Lincoln Park to purchase up to 30,000 shares of Common Stock on such purchase date, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company
        delivers such written notice to Lincoln Park (each, a &#8220;regular purchase&#8221;). The maximum number of shares the Company may sell to Lincoln Park in a regular purchase may be increased by certain amounts to up to 90,000 shares, with the applicable
        maximum share limit determined by whether the closing sale price per share of Common Stock as reported on The Nasdaq Capital Market on the applicable purchase date for such regular purchase equals or exceeds certain minimum price thresholds set
        forth in the Purchase Agreement, in each case, subject to adjustment for any recapitalization, non-cash dividend, forward or reverse stock split or other similar transactions as provided in the Purchase Agreement; however, Lincoln Park&#8217;s maximum
        purchase commitment in any single regular purchase may not exceed $1,000,000.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In addition to regular purchases, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares
        that the Company is then able to sell to Lincoln Park in a regular purchase, the Company may, in its sole discretion, direct Lincoln Park to purchase additional shares of Common Stock in &#8220;accelerated purchases&#8221; and &#8220;additional accelerated
        purchases,&#8221; as set forth in the Purchase Agreement. The purchase price per share of Common Stock sold in each such accelerated purchase and additional accelerated purchase, if any, will&#160; calculated in accordance with the pricing terms for an
        accelerated purchase and an additional accelerated purchase, as applicable, set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the
        Purchase Agreement.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Under the Purchase Agreement, the Company will control the timing and amount of sales of Common Stock to Lincoln Park, if any.
        Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions set forth in the Purchase Agreement.&#160; Actual
        sales of shares of Common Stock to Lincoln Park, if any, will depend on a variety of factors to be determined by the Company from time to time, including, among others, general market conditions, the trading prices for the Common Stock, and
        determinations by the Company as to the appropriate sources of funding for the Company and its operations.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under applicable Nasdaq listing rules, the aggregate number of shares of Common Stock that the Company may issue to Lincoln Park under the
          Purchase Agreement cannot exceed 19.99% of the shares of Common Stock issued and outstanding immediately prior to the execution of the Purchase Agreement (the &#8220;<span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="text-decoration: underline;">Exchange Cap</span></span>&#8221;),
          unless (i) the Company first obtains stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with applicable Nasdaq listing rules, or (ii) at the time the Company has issued shares of Common Stock equal to
          the Exchange Cap and at all times thereafter, the average price per share of Common Stock for all shares of Common Stock sold by the Company to Lincoln Park under the Purchase Agreement equals or exceeds $3.6094 per share (representing the lower
          of the official closing price of the Common Stock on Nasdaq on the trading day immediately preceding the date of the Purchase Agreement and the average official closing price of the Common Stock on Nasdaq for the five consecutive trading days
          ending on the trading day immediately preceding the date of the Purchase Agreement, as adjusted under applicable Nasdaq rules to take into account the issuance of shares of Common Stock to Lincoln Park for non-cash consideration as payment of the
          commitment fee described below), such that the Exchange Cap limitation would no longer apply to issuances and sales of Common Stock by the Company to Lincoln Park under the Purchase Agreement under applicable Nasdaq listing rules.</div>

      </div>

      <div>&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Additionally, Company may not direct Lincoln Park to purchase any shares of Common Stock under the Purchase Agreement if such
        purchase would result in Lincoln Park beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">There are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in
        the Purchase Agreement or Registration Rights Agreement, except the Company is prohibited, subject to certain exceptions, during the term of the Purchase Agreement or 90 days following the effective date of the termination of the Purchase
        Agreement, whichever concludes earlier, from entering into an agreement to effect an &#8220;equity line of credit&#8221; or other similar offering in which the Company may issue and sell Common Stock, from time to time over a certain period of time, at future
        determined prices based on the market prices of the Common Stock at the time of each such issuance and sale.&#160; Lincoln Park has agreed not to engage in any short sales of the Common Stock or hedging transaction that establishes a net short position
        in the Common Stock during the term of the Purchase Agreement.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock in accordance with the Purchase Agreement, the
        Company has issued 73,659 shares of Common Stock to Lincoln Park as a commitment fee.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, conditions and
        indemnification obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time with one business day&#8217;s prior written notice to Lincoln Park, at no cost or penalty.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Purchase Agreement and the Registration Rights Agreement is only a summary and is qualified in
        its entirety by reference to the full text of the Purchase Agreement and the Registration Rights Agreement, copies of which are attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and incorporated herein by reference. The
        representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed
        upon by the contracting parties.</div>

      <div>&#160;</div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The offer and sale of the Common Stock pursuant to the Purchase Agreement have not been registered under the Securities Act or any
        state securities laws. The Common Stock may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an
        offer to sell or the solicitation of an offer to buy the Common Stock described herein or therein.</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In the Purchase Agreement, Lincoln Park represented to the Company that it is an &#8220;accredited investor&#8221;, as defined in Rule 501
        promulgated under the Securities Act, and the Company&#8217;s offer and sale of the Common Stock under the Purchase Agreement are being made in reliance upon the exemptions from the registration requirements of the Securities Act pursuant to Section
        4(a)(2) thereof and Rule 506(b) of Regulation D promulgated thereunder.</div>

      <div>&#160;</div>

      <div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 3.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Unregistered Sales of Equity Securities.</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

        </div>

      </div>

    </div>

    <div>
      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.02.</div>

      <div style="text-align: justify; text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Statements and Exhibits.</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

        </div>

      </div>

    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"> <br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12.38%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit<span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
                  </span>Number</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td style="width: 87%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
                  </span>Description</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 12.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10050812_ex10-1.htm">10.1</a></div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Purchase Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc. and Lincoln Park Capital Fund, LLC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12.38%; vertical-align: top;">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><a href="brhc10050812_ex10-2.htm">10.2</a></div>
            </td>

    <td style="width: 1%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 87%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Registration Rights Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc. and Lincoln Park Capital Fund, LLC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 12.38%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">104</div>
            </td>

    <td style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td style="width: 87%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    <div style="text-align: center;"><span style="font-weight: bold;">SIGNATURE</span> </div>

    <div><br />
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
      duly authorized.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps;">Eterna Therapeutics Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td colspan="3" style="vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dated: April 11<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">, 2023</span></div>
          </td>

    <td style="width: 3%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
          </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Andrew Jackson</div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 45%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Chief Financial Officer</div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

  </tr>


</table>
    <div><br />
    </div>

    <div><br />
    </div>

  </div>

  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10050812_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.1</div>
      <div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: center; font-weight: bold;">PURCHASE AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">PURCHASE AGREEMENT</font> (the &#8220;<u>Agreement</u>&#8221;), dated as of April 5, 2023, by and between <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, a
        Delaware corporation (the &#8220;<u>Company</u>&#8221;), and <font style="font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC</font>, an Illinois limited liability company (the &#8220;<u>Investor</u>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">WHEREAS:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Ten Million Dollars ($10,000,000)
        of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;<u>Common Stock</u>&#8221;).&#160; The shares of Common Stock to be purchased hereunder are referred to herein as the &#8220;<u>Purchase Shares</u>.&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the
        Company and the Investor, intending to be legally bound, hereby agree as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">CERTAIN DEFINITIONS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">For purposes of this Agreement, the following terms shall have the following meanings:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Date</u>&#8221; means, with respect to any Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, the Business Day immediately following the applicable
        Purchase Date with respect to the corresponding Regular Purchase referred to in clause (i) of the second sentence of <u>Section 2(b)</u> hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Minimum Price Threshold</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, the minimum per share price threshold
        set forth by the Company in the applicable Accelerated Purchase Notice; <u>provided</u>, that if the Company shall not have specified such threshold, then the Accelerated Purchase Minimum Price Threshold shall be seventy-five percent (75%) of the
        Closing Sale Price of the Common Stock on the applicable Purchase Date with respect to the corresponding Regular Purchase referred to in clause (i) of the second sentence of <u>Section 2(b)</u> hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Notice</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, an irrevocable written notice from the Company to the
        Investor directing the Investor to purchase the number of Purchase Shares specified by the Company therein as the Accelerated Purchase Share Amount to be purchased by the Investor (such specified Accelerated Purchase Share Amount subject to
        adjustment in accordance with <u>Section 2(b)</u> hereof as necessary to give effect to the Purchase Share amount limitations applicable to such Accelerated Purchase Share Amount as set forth in this Agreement) at the applicable Accelerated
        Purchase Price on the applicable Accelerated Purchase Date for such Accelerated Purchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Price</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, ninety-six percent (96%) of the lower of (i) the VWAP for
        the period beginning at 9:30:01 a.m., Eastern time, on the applicable Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official open (or commencement) of trading on the Principal Market on such
        applicable Accelerated Purchase Date (the &#8220;<u>Accelerated Purchase Commencement Time</u>&#8221;), and ending at the earliest of (A) 4:00:00 p.m., Eastern time, on such applicable Accelerated Purchase Date, or such other time publicly announced by the
        Principal Market as the official close of trading on the Principal Market on such applicable Accelerated Purchase Date, (B) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase, that the total number
        (or volume) of shares of Common Stock traded on the Principal Market has exceeded the applicable Accelerated Purchase Share Volume Maximum, and (C) such time, from and after the Accelerated Purchase Commencement Time for such Accelerated Purchase,
        that the Sale Price has fallen below the applicable Accelerated Purchase Minimum Price Threshold (such earliest time described in (i)(A), (i)(B) and (i)(C) above, the &#8220;<u>Accelerated Purchase Termination Time</u>&#8221;), and (ii) the Closing Sale Price
        of the Common Stock on such applicable Accelerated Purchase Date (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%-%-%-->
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Share Amount</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, the number of Purchase Shares directed by the
        Company to be purchased by the Investor in an Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company to be purchased by the Investor pursuant to
        the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i) of the second sentence of <u>Section 2(b)</u> hereof (subject to the Purchase Share limitations contained in <u>Section 2(a)</u> hereof)
        and (ii) an amount equal to (A) the Accelerated Purchase Share Percentage multiplied by (B) the total number (or volume) of shares of Common Stock traded on the Principal Market during the period on the applicable Accelerated Purchase Date
        beginning at the Accelerated Purchase Commencement Time for such Accelerated Purchase and ending at the Accelerated Purchase Termination Time for such Accelerated Purchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Share Percentage</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, thirty percent (30%).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Accelerated Purchase Share Volume Maximum</u>&#8221; means, with respect to an Accelerated Purchase made pursuant to <u>Section 2(b)</u> hereof, a number of shares of Common Stock equal
        to (i) the number of Purchase Shares specified by the Company in the applicable Accelerated Purchase Notice as the Accelerated Purchase Share Amount to be purchased by the Investor in such Accelerated Purchase, divided by (ii) the Accelerated
        Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Date</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, the Business Day (i) that is the
        Accelerated Purchase Date with respect to the corresponding Accelerated Purchase referred to in clause (i) of the proviso in the second sentence of<u> Section 2(c)</u> hereof and (ii) on which the Investor receives, prior to 1:00 p.m., Eastern
        time, on such Business Day, a valid Additional Accelerated Purchase Notice for such Additional Accelerated Purchase in accordance with this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Minimum Price Threshold</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, the minimum per
        share price threshold set forth by the Company in the applicable Additional Accelerated Purchase Notice; <u>provided</u>, that if the Company shall not have specified such threshold, then the Additional Accelerated Purchase Minimum Price Threshold
        shall be seventy-five percent (75%) of the Closing Sale Price of the Common Stock on the Business Day immediately preceding the applicable Additional Accelerated Purchase Date with respect to such Additional Accelerated Purchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Notice</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, an irrevocable written notice from
        the Company to the Investor directing the Investor to purchase the number of Purchase Shares specified by the Company therein as the Additional Accelerated Purchase Share Amount to be purchased by the Investor (such specified Additional Accelerated
        Purchase Share Amount subject to adjustment in accordance with <u>Section 2(c)</u> hereof as necessary to give effect to the Purchase Share amount limitations applicable to such Additional Accelerated Purchase Share Amount as set forth in this
        Agreement) at the applicable Additional Accelerated Purchase Price on the applicable Additional Accelerated Purchase Date for such Additional Accelerated Purchase.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-2-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Price</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, ninety-six percent (96%) of the
        lower of (i)&#160;the VWAP for the period on the applicable Additional Accelerated Purchase Date, beginning at the latest of (A) the applicable Accelerated Purchase Termination Time with respect to the corresponding Accelerated Purchase referred to in
        clause (i) of the proviso in the second sentence of <u>Section 2(c)</u> hereof on such Additional Accelerated Purchase Date, (B) the applicable Additional Accelerated Purchase Termination Time with respect to the most recently completed prior
        Additional Accelerated Purchase on such Additional Accelerated Purchase Date, as applicable, and (C) the time at which all Purchase Shares subject to all prior Accelerated Purchases and Additional Accelerated Purchases (as applicable), including,
        without limitation, those that have been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, have theretofore been received by the
        Investor as DWAC Shares in accordance with this Agreement (such latest of (i)(A), (i)(B) and (i)(C) above, the &#8220;<u>Additional Accelerated Purchase Commencement Time</u>&#8221;), and ending at the earliest of (X) 4:00 p.m., Eastern time, on such
        Additional Accelerated Purchase Date, or such other time publicly announced by the Principal Market as the official close of trading on the Principal Market on such Additional Accelerated Purchase Date, (Y) such time, from and after the Additional
        Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the total number (or volume) of shares of Common Stock traded on the Principal Market has exceeded the applicable Additional Accelerated Purchase Share Volume
        Maximum, and (Z) such time, from and after the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase, that the Sale Price has fallen below the applicable Additional Accelerated Purchase Minimum Price Threshold
        (such earliest of (i)(X), (i)(Y) and (i)(Z) above, the &#8220;<u>Additional Accelerated Purchase Termination Time</u>&#8221;), and (ii) the Closing Sale Price of the Common Stock on such Additional Accelerated Purchase Date (to be appropriately adjusted for
        any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Share Amount</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, the number of Purchase
        Shares directed by the Company to be purchased by the Investor on an Additional Accelerated Purchase Notice, which number of Purchase Shares shall not exceed the lesser of (i) 300% of the number of Purchase Shares directed by the Company to be
        purchased by the Investor pursuant to the corresponding Regular Purchase Notice for the corresponding Regular Purchase referred to in clause (i) of the proviso in the second sentence of <u>Section 2(c)</u> hereof (subject to the Purchase Share
        limitations contained in <u>Section 2(a)</u> hereof) and (ii) an amount equal to (A) the Additional Accelerated Purchase Share Percentage multiplied by (B) the total number (or volume) of shares of Common Stock traded on the Principal Market
        during the period on the applicable Additional Accelerated Purchase Date beginning at the Additional Accelerated Purchase Commencement Time for such Additional Accelerated Purchase and ending at the Additional Accelerated Purchase Termination Time
        for such Additional Accelerated Purchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Share Percentage</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, thirty percent (30%).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Additional Accelerated Purchase Share Volume Maximum</u>&#8221; means, with respect to an Additional Accelerated Purchase made pursuant to <u>Section 2(c)</u> hereof, a number of shares
        of Common Stock equal to (i) the number of Purchase Shares specified by the Company in the applicable Additional Accelerated Purchase Notice as the Additional Accelerated Purchase Share Amount to be purchased by the Investor in such Additional
        Accelerated Purchase, divided by (ii) the Additional Accelerated Purchase Share Percentage (to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-3-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Alternate Adjusted Regular Purchase Share Limit</u>&#8221; means, with respect to a Regular Purchase made pursuant to <u>Section 2(a)</u> hereof, the maximum number of Purchase Shares
        which, taking into account the applicable per share Purchase Price therefor calculated in accordance with this Agreement, would enable the Company to deliver to the Investor, on the applicable Purchase Date for such Regular Purchase, a Regular
        Purchase Notice for a Purchase Amount equal to, or as closely approximating without exceeding, One Hundred Fifty Thousand Dollars ($150,000).</div>
      <div style="text-align: justify; text-indent: 90pt;"><br>
        <div style="text-indent: 36pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Available Amount</u>&#8221; means, initially, Ten Million Dollars ($10,000,000) in the aggregate, which amount shall be reduced by the Purchase Amount each time the Investor purchases Purchase Shares
          pursuant to <u>Section 2</u> hereof.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Average Price</u>&#8221; means a price per Purchase Share (rounded to the nearest tenth of a cent) equal to the quotient obtained by dividing (i) the aggregate gross purchase price paid by
        the Investor for all Purchase Shares purchased pursuant to this Agreement, by (ii) the aggregate number of Purchase Shares issued pursuant to this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Bankruptcy Law</u>&#8221; means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Base Price</u>&#8221; means a price per Purchase Share equal to the sum of (i) the Signing Market Price and (ii) $0.2594 (subject to adjustment for any reorganization, recapitalization,
        non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of this Agreement).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Business Day</u>&#8221; means any day on which the Principal Market is open for trading, including any day on which the Principal Market is open for trading for a period of time less than
        the customary time.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Closing Sale Price</u>&#8221; means, for any security as of any date, the last closing sale price for such security on the Principal Market as reported by the Principal Market.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Confidential Information</u>&#8221; means any information disclosed by either party to the other party, either directly or indirectly, in writing, orally or by inspection of tangible
        objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated as &#8220;Confidential,&#8221; &#8220;Proprietary&#8221; or some similar designation. Information communicated orally shall be considered Confidential
        Information if such information is confirmed in writing as being Confidential Information within ten (10) Business Days after the initial disclosure. Confidential Information may also include information disclosed to a disclosing party by third
        parties, who, to the knowledge of the receiving party, owe a duty or other obligation of confidentiality to the party about which such information pertains. Confidential Information shall not, however, include any information which (i) was publicly
        known and made generally available in the public domain prior to the time of disclosure by the disclosing party; (ii) becomes publicly known and made generally available after disclosure by the disclosing party to the receiving party through no
        action or inaction of the receiving party; (iii) is already in the possession of the receiving party without confidential restriction at the time of disclosure by the disclosing party as shown by the receiving party&#8217;s files and records immediately
        prior to the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach of such third party&#8217;s obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to
        the disclosing party&#8217;s Confidential Information, as shown by documents and other competent evidence in the receiving party&#8217;s possession; or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the
        disclosing party prompt written notice of such requirement prior to such disclosure and assistance in obtaining an order protecting the information from public disclosure.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-4-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Custodian</u>&#8221; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>DTC</u>&#8221; means The Depository Trust Company, or any successor performing substantially the same function for the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>DWAC Shares</u>&#8221; means shares of Common Stock that are (i) issued in electronic form, (ii) freely tradable and transferable and without restriction on resale and (iii) timely
        credited by the Company to the Investor&#8217;s or its designee&#8217;s specified Deposit/Withdrawal at Custodian (DWAC) account with DTC under its Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing
        substantially the same function.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Floor Price</u>&#8221; means, with respect to a Regular Purchase made pursuant to <u>Section 2(a)</u> hereof, $0.50, which shall be appropriately adjusted for any reorganization,
        recapitalization, non-cash dividend, stock split or other similar transaction and, effective upon the consummation of any such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction, the Floor Price shall mean
        the <u>lower</u> of (i) the adjusted price and (ii) $0.50.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Fully Adjusted Regular Purchase Share Limit</u>&#8221; means, with respect to any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction from and
        after the date of this Agreement, the Regular Purchase Share Limit (as defined in <u>Section 2(a) </u>hereof) in effect on the applicable date of determination, after giving effect to the full proportionate adjustment thereto made pursuant to <u>Section







          2(a)</u> hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split or other similar transaction.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Material Adverse Effect</u>&#8221; means any material adverse effect on (i)&#160;the enforceability of any Transaction Document, (ii)&#160;the results of operations, assets, business or financial
        condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse effect that resulted exclusively from (A)&#160;any change in the United States or foreign economies or securities or financial markets in general that does
        not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B)&#160;any change that generally affects the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on the
        Company and its Subsidiaries, taken as a whole, (C)&#160;any change arising in connection with pandemics, earthquakes, hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities,
        acts of war, sabotage or terrorism or military actions, (D)&#160;any action taken, or omitted to be taken, by the Investor, its affiliates or its or their respective successors and assigns with respect to the transactions contemplated by this Agreement,
        (E)&#160;the effect of any change in applicable laws or accounting rules that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, or (F)&#160;any change resulting from compliance with terms of this Agreement or the
        consummation of the transactions contemplated by this Agreement, or (iii)&#160;the Company&#8217;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document to be performed as of the date of determination.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Maturity Date</u>&#8221; means the first day of the month immediately following the twenty-four (24) month anniversary of the Commencement Date.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-5-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>PEA Period</u>&#8221; means the period commencing at 9:30 a.m., Eastern time, on the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Business
        Day immediately prior to the filing of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as such term is defined in the Registration Rights Agreement), and ending at 9:30 a.m., Eastern
        time, on the Business Day immediately following, the effective date of any post-effective amendment to the Registration Statement (as defined herein) or New Registration Statement (as such term is defined in the Registration Rights Agreement).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Person</u>&#8221; means an individual or entity including but not limited to any limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated
        organization and a government or any department or agency thereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(gg)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Principal Market</u>&#8221; means The Nasdaq Capital Market (or any nationally recognized successor thereto); provided, however, that in the event the Company&#8217;s Common Stock is not listed
        on The Nasdaq Capital Market (or any nationally recognized successor thereto) but is then listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or the OTCQB or
        the OTCQX operated by OTC Markets Group, Inc. (or any nationally recognized successor to any of the foregoing), then the &#8220;<u>Principal Market</u>&#8221; shall mean such other market or exchange on which the Company&#8217;s Common Stock is then listed or
        traded.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(hh)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Purchase Amount</u>&#8221; means, with respect to any Regular Purchase, any Accelerated Purchase or any Additional Accelerated Purchase made hereunder, as applicable, the portion of the
        Available Amount to be purchased by the Investor pursuant to <u>Section 2</u> hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Purchase Date</u>&#8221; means, with respect to a Regular Purchase made pursuant to <u>Section 2(a)</u> hereof, the Business Day on which the Investor receives, after 4:00 p.m., Eastern
        time, but prior to 6:00 p.m., Eastern time, on such Business Day, a valid Regular Purchase Notice for such Regular Purchase in accordance with this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(jj)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Purchase Price</u>&#8221; means, with respect to any Regular Purchase made pursuant to <u>Section 2(a)</u> hereof, the lower of: (i) the lowest Sale Price on the applicable Purchase Date
        for such Regular Purchase and (ii) the arithmetic average of the three (3) lowest Closing Sale Prices for the Common Stock during the ten (10) consecutive Business Days ending on the Business Day immediately preceding such Purchase Date for such
        Regular Purchase (in each case, to be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs on or after the date of this Agreement).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(kk)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Regular Purchase Notice</u>&#8221; means, with respect to any Regular Purchase pursuant to <u>Section 2(a)</u> hereof, an irrevocable written notice from the Company to the Investor
        directing the Investor to buy such applicable amount of Purchase Shares at the applicable Purchase Price as specified by the Company therein on the applicable Purchase Date for such Regular Purchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Sale Price</u>&#8221; means any trade price for the shares of Common Stock on the Principal Market as reported by the Principal Market.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(mm)&#160;&#160;&#160;&#160;&#160; &#8220;<u>SEC</u>&#8221; means the U.S. Securities and Exchange Commission.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(nn)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Securities</u>&#8221; means, collectively, the Purchase Shares and the Commitment Shares.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(oo)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-6-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(pp)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Signing Market Price</u>&#8221; means $3.35, representing the official closing price of the Common Stock on The Nasdaq Capital Market (as reflected on Nasdaq.com) on the trading day
        immediately preceding the date of this Agreement.<br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div style="text-indent: 36pt;">(qq)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Subsidiary</u>&#8221; means any Person the Company wholly owns or controls, or in which the Company, directly or indirectly, owns a majority of the voting stock or similar voting interest, in each case that
        would be disclosable pursuant to Item 601(b)(21) of Regulation S-K promulgated under the Securities Act.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(rr)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Transaction Documents</u>&#8221; means, collectively, this Agreement and the schedules and exhibits hereto, the Registration Rights Agreement and the schedules and exhibits thereto, and
        each of the other agreements, documents, certificates and instruments entered into or furnished by the parties hereto in connection with the transactions contemplated hereby and thereby.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(ss)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>Transfer Agent</u>&#8221; means Computershare Trust Company, N.A., or such other Person who is then serving as the transfer agent for the Company in respect of the Common Stock.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(tt)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<u>VWAP</u>&#8221; means in respect of an Accelerated Purchase Date and an Additional Accelerated Purchase Date, as applicable, the volume weighted average price of the Common Stock on the
        Principal Market, as reported on the Principal Market or by another reputable source such as Bloomberg, L.P.</div>
      <div>&#160;</div>
      <div style="margin-left: 36pt; font-weight: bold;">2.&#160; PURCHASE OF COMMON STOCK.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Subject to the terms and conditions set forth in this Agreement, the Company has the right, but not the obligation, to sell to the Investor, in the Company&#8217;s sole and absolute discretion, and the
        Investor has the obligation to purchase from the Company, Purchase Shares as follows:</div>
      <div>&#160;<br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-7-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Commencement of Regular Sales of Common Stock</u>.&#160; Upon the satisfaction of all of the conditions set forth in <u>Sections 7</u> and <u>8</u> hereof (the &#8220;<u>Commencement</u>&#8221; and
        the date of satisfaction of such conditions the &#8220;<u>Commencement Date</u>&#8221;) and thereafter, the Company shall have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of a Regular Purchase Notice from time to
        time, to purchase up to Thirty Thousand (30,000) Purchase Shares, subject to adjustment as set forth below in this <u>Section 2(a)</u> (such maximum number of Purchase Shares, as may be adjusted from time to time, the &#8220;<u>Regular Purchase Share
          Limit</u>&#8221;), at the Purchase Price on the Purchase Date (each such purchase a &#8220;<u>Regular Purchase</u>&#8221;); <u>provided</u>, <u>however</u>, that (i) the Regular Purchase Share Limit shall be increased to Forty Thousand (40,000) Purchase Shares
        if the Closing Sale Price of the Common Stock on the applicable Purchase Date is not below $4.50, (ii) the Regular Purchase Share Limit shall be increased to Fifty Thousand (50,000) Purchase Shares if the Closing Sale Price of the Common Stock on
        the applicable Purchase Date is not below $5.00, and (iii) the Regular Purchase Share Limit shall be increased to Ninety Thousand (90,000) Purchase Shares if the Closing Sale Price of the Common Stock on the applicable Purchase Date is not below
        $6.00 (all of which share and dollar amounts shall be appropriately proportionately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction; <u>provided</u> that if, after giving effect to the
        full proportionate adjustment to the Regular Purchase Share Limit therefor, the Fully Adjusted Regular Purchase Share Limit then in effect would preclude the Company from delivering to the Investor a Regular Purchase Notice hereunder for a Purchase
        Amount (calculated by multiplying (X) the number of Purchase Shares equal to the Fully Adjusted Regular Purchase Share Limit, by (Y) the Purchase Price per Purchase Share covered by such Regular Purchase Notice on the applicable Purchase Date
        therefor) equal to or greater than One Hundred Fifty Thousand Dollars ($150,000), the Regular Purchase Share Limit for such Regular Purchase Notice shall not be fully adjusted to equal the applicable Fully Adjusted Regular Purchase Share Limit, but
        rather the Regular Purchase Share Limit for such Regular Purchase Notice shall be adjusted to equal the applicable Alternate Adjusted Regular Purchase Share Limit as of the applicable Purchase Date for such Regular Purchase Notice); and <u>provided</u>,
        <u>further</u>, <u>however</u>, that the Investor&#8217;s committed obligation under any single Regular Purchase, other than any Regular Purchase with respect to which an Alternate Adjusted Regular Purchase Share Limit shall apply, shall not exceed One
        Million Dollars ($1,000,000). If the Company delivers any Regular Purchase Notice for a Purchase Amount in excess of the limitations contained in the immediately preceding sentence, such Regular Purchase Notice shall be void <font style="font-style: italic;">ab initio</font> to the extent of the amount by which the number of Purchase Shares set forth in such Regular Purchase Notice exceeds the number of Purchase Shares that the Company is permitted to include in such
        Purchase Notice in accordance herewith, and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Regular Purchase Notice; <u>provided</u>, <u>however</u>, that the Investor shall remain obligated to
        purchase the number of Purchase Shares that the Company is permitted to include in such Regular Purchase Notice. The Company may deliver a Regular Purchase Notice to the Investor as often as every Business Day, so long as (i) the Closing Sale Price
        of the Common Stock on such Business Day is not less than the Floor Price and (ii) all Purchase Shares subject to all prior Regular Purchases have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement.
        Notwithstanding the foregoing, the Company shall not deliver any Regular Purchase Notices to the Investor during the PEA Period.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Accelerated Purchases</u>.&#160; Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in addition to Regular Purchases as described in <u>Section
          2(a)</u> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its delivery to the Investor of an Accelerated Purchase Notice from time to time in accordance with this Agreement, to purchase the
        applicable Accelerated Purchase Share Amount at the Accelerated Purchase Price on the Accelerated Purchase Date therefor in accordance with this Agreement (each such purchase, an &#8220;<u>Accelerated Purchase</u>&#8221;). The Company may deliver an
        Accelerated Purchase Notice to the Investor only (i) on a Purchase Date on which the Company also properly submitted a Regular Purchase Notice providing for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share
        Limit then in effect on such Purchase Date in accordance with this Agreement (including, without limitation, giving effect to any automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale Price of the Common Stock
        exceeding certain thresholds set forth in <u>Section 2(a)</u> above on such Purchase Date and such other adjustments to the Regular Purchase Share Limit, in each case pursuant to <u>Section 2(a)</u> above) and (ii) if all Purchase Shares subject
        to all Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases prior to the Regular Purchase Date referred to in clause (i) hereof (as applicable) have theretofore been received by the Investor as DWAC Shares in accordance
        with this Agreement. If the Company delivers any Accelerated Purchase Notice directing the Investor to purchase an amount of Purchase Shares that exceeds the Accelerated Purchase Share Amount that the Company is then permitted to include in such
        Accelerated Purchase Notice, such Accelerated Purchase Notice shall be void <font style="font-style: italic;">ab initio</font> to the extent of the amount by which the number of Purchase Shares set forth in such Accelerated Purchase Notice exceeds
        the Accelerated Purchase Share Amount that the Company is then permitted to include in such Accelerated Purchase Notice (which shall be confirmed in an Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such
        excess Purchase Shares in respect of such Accelerated Purchase Notice; <u>provided</u>, <u>however</u>, that the Investor shall remain obligated to purchase the Accelerated Purchase Share Amount which the Company is permitted to include in such
        Accelerated Purchase Notice. Within one (1) Business Day after each Accelerated Purchase Date for an Accelerated Purchase, the Investor will provide to the Company a written confirmation of such Accelerated Purchase setting forth the applicable
        Accelerated Purchase Share Amount and Accelerated Purchase Price for such Accelerated Purchase (each, an &#8220;<u>Accelerated Purchase Confirmation</u>&#8221;). Notwithstanding the foregoing, the Company shall not deliver any Accelerated Purchase Notices to
        the Investor during the PEA Period.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-8-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Additional Accelerated Purchases</u>.&#160; Subject to the terms and conditions of this Agreement, from and after the Commencement Date, in addition to purchases of Purchase Shares as
        described in <u>Section 2(a)</u> and <u>Section 2(b)</u> above, the Company shall also have the right, but not the obligation, to direct the Investor, by its timely delivery to the Investor of an Additional Accelerated Purchase Notice on an
        Additional Accelerated Purchase Date in accordance with this Agreement, to purchase the applicable Additional Accelerated Purchase Share Amount at the applicable Additional Accelerated Purchase Price therefor in accordance with this Agreement (each
        such purchase, an &#8220;<u>Additional Accelerated Purchase</u>&#8221;). The Company may deliver multiple Additional Accelerated Purchase Notices to the Investor on an Additional Accelerated Purchase Date; <u>provided</u>, <u>however</u>, that the Company
        may deliver an Additional Accelerated Purchase Notice to the Investor only (i) on a Business Day that is also the Accelerated Purchase Date for an Accelerated Purchase with respect to which the Company properly submitted to the Investor an
        Accelerated Purchase Notice in accordance with this Agreement on the applicable Purchase Date for a Regular Purchase of a number of Purchase Shares not less than the Regular Purchase Share Limit then in effect in accordance with this Agreement
        (including, without limitation, giving effect to any automatic increase to the Regular Purchase Share Limit as a result of the Closing Sale Price of the Common Stock exceeding certain thresholds set forth in <u>Section 2(a)</u> above on such
        Purchase Date and any other adjustments to the Regular Purchase Share Limit, in each case pursuant to <u>Section 2(a)</u> above), and (ii) if all Purchase Shares subject to all prior Regular Purchases, Accelerated Purchases and Additional
        Accelerated Purchases, including, without limitation, those that have been effected on the same Business Day as the applicable Additional Accelerated Purchase Date with respect to which the applicable Additional Accelerated Purchase relates, in
        each case have theretofore been received by the Investor as DWAC Shares in accordance with this Agreement. If the Company delivers any Additional Accelerated Purchase Notice directing the Investor to purchase an amount of Purchase Shares that
        exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted to include in such Additional Accelerated Purchase Notice, such Additional Accelerated Purchase Notice shall be void <font style="font-style: italic;">ab
          initio</font> to the extent of the amount by which the number of Purchase Shares set forth in such Additional Accelerated Purchase Notice exceeds the Additional Accelerated Purchase Share Amount that the Company is then permitted to include in
        such Additional Accelerated Purchase Notice (which shall be confirmed in an Additional Accelerated Purchase Confirmation), and the Investor shall have no obligation to purchase such excess Purchase Shares in respect of such Additional Accelerated
        Purchase Notice; <u>provided</u>, <u>however</u>, that the Investor shall remain obligated to purchase the Additional Accelerated Purchase Share Amount which the Company is permitted to include in such Additional Accelerated Purchase Notice.
        Within one (1) Business Day after each Additional Accelerated Purchase Date, the Investor will provide to the Company a written confirmation of each Additional Accelerated Purchase on such Additional Accelerated Purchase Date setting forth the
        applicable Additional Accelerated Purchase Share Amount and Additional Accelerated Purchase Price for each such Additional Accelerated Purchase on such Additional Accelerated Purchase Date (each, an &#8220;<u>Additional Accelerated Purchase Confirmation</u>&#8221;).






        Notwithstanding the foregoing, the Company shall not deliver any Additional Accelerated Purchase Notices to the Investor during the PEA Period.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-9-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Payment for Purchase Shares.</u>&#160; For each Regular Purchase, the Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Regular Purchase as
        full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day that the Investor receives such Purchase Shares, if such Purchase Shares are received by the Investor before 1:00 p.m., Eastern time,
        or, if such Purchase Shares are received by the Investor after 1:00 p.m., Eastern time, the next Business Day. For each Accelerated Purchase and each Additional Accelerated Purchase, the Investor shall pay to the Company an amount equal to the
        Purchase Amount with respect to such Accelerated Purchase and Additional Accelerated Purchase, respectively, as full payment for such Purchase Shares via wire transfer of immediately available funds on the second Business Day following the date
        that the Investor receives such Purchase Shares. If the Company or the Transfer Agent shall fail for any reason or for no reason to electronically transfer any Purchase Shares as DWAC Shares in respect of a Regular Purchase, an Accelerated Purchase
        or an Additional Accelerated Purchase (as applicable) within two (2) Business Days following the receipt by the Company of the Purchase Price, Accelerated Purchase Price and Additional Accelerated Purchase Price, respectively, therefor in
        compliance with this <u>Section 2(d)</u>, and if on or after such Business Day the Investor purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Investor of such Purchase Shares
        that the Investor anticipated receiving from the Company in respect of such Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase (as applicable), then the Company shall, within two (2) Business Days after the Investor&#8217;s
        request, either (i) pay cash to the Investor in an amount equal to the Investor&#8217;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the &#8220;<u>Cover Price</u>&#8221;), at which point the Company&#8217;s
        obligation to deliver such Purchase Shares as DWAC Shares shall terminate, or (ii)&#160; promptly honor its obligation to deliver to the Investor such Purchase Shares as DWAC Shares and pay cash to the Investor in an amount equal to the excess (if any)
        of the Cover Price over the total Purchase Amount paid by the Investor pursuant to this Agreement for all of the Purchase Shares to be purchased by the Investor in connection with such Regular Purchase, Accelerated Purchase and Additional
        Accelerated Purchase (as applicable). The Company shall not issue any fraction of a share of Common Stock upon any Regular Purchase, Accelerated Purchase or Additional Accelerated Purchase.&#160; If the issuance would result in the issuance of a
        fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share. All payments made under this Agreement shall be made in lawful currency of the United States of America by
        wire transfer of immediately available funds to such account as the Company (or the Investor, as applicable) may from time to time designate by written notice in accordance with the provisions of this Agreement. Whenever any amount expressed to be
        due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is a Business Day.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance with Rules of Principal Market</u>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 99pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Exchange Cap</u>.&#160; Subject to <u>Section 2(e)(ii)</u> below, the Company shall not issue or sell any shares of Common Stock pursuant to this Agreement, and the Investor shall not
        purchase or acquire any shares of Common Stock from the Company pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of shares of Common Stock that would be issued pursuant to this Agreement and the
        transactions contemplated hereby would exceed 1,024,901 (such number of shares equal to 19.99% of the shares of Common Stock issued and outstanding immediately prior to the execution of this Agreement), which number of shares shall be (i) reduced,
        on a share-for-share basis, by the number of shares of Common Stock issued or issuable pursuant to any transaction or series of transactions that may be aggregated with the transactions contemplated by this Agreement under applicable rules of The
        Nasdaq Stock Market and (ii) appropriately adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction that occurs after the date of this Agreement (such maximum number of shares, the &#8220;<u>Exchange
          Cap</u>&#8221;), unless and until the Company elects to obtain stockholder approval of the issuance of Common Stock as contemplated by this Agreement, and the stockholders of the Company have in fact approved the issuance of Common Stock as
        contemplated by this Agreement in accordance with the applicable rules of The Nasdaq Stock Market. For the avoidance of doubt, the Company may, but shall be under no obligation to, request its stockholders to approve the issuance of Common Stock as
        contemplated by this Agreement; <u>provided</u>, that if stockholder approval is not obtained in accordance with this <u>Section 2(e)(i)</u>, the Exchange Cap shall be applicable for all purposes of this Agreement and the transactions
        contemplated hereby at all times during the term of this Agreement (except as set forth in <u>Section 2(e)(ii)</u> below).</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-10-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 99pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>At-Market Transaction</u>. Notwithstanding <u>Section 2(e)(i)</u> above, the Exchange Cap shall not be applicable for any purposes of this Agreement and the transactions
        contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed the Base Price (it being hereby acknowledged and agreed that the Exchange Cap shall be applicable for all purposes of this Agreement
        and the transactions contemplated hereby at all other times during the term of this Agreement, unless the stockholder approval referred to in <u>Section 2(e)(i)</u> is obtained). The parties acknowledge and agree that the Signing Market Price used
        to determine the Base Price hereunder represents the lower of (i) the official closing price of the Common Stock on The Nasdaq Capital Market (as reflected on Nasdaq.com) on the trading day immediately preceding the date of this Agreement and (ii)
        the average official closing price of the Common Stock on The Nasdaq Capital Market (as reflected on Nasdaq.com) for the five (5) consecutive trading days ending on the trading day immediately preceding the date of this Agreement.</div>
      <div style="text-indent: 99pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 99pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>General</u>.&#160; The Company shall not issue any shares of Common Stock pursuant to this Agreement if such issuance would reasonably be expected to result in (A) a violation of the
        Securities Act or (B) a breach of the rules and regulations of the Principal Market. The provisions of this <u>Section 2(e)</u> shall be implemented in a manner otherwise than in strict conformity with the terms hereof only if necessary to ensure
        compliance with the Securities Act and the rules and regulations of the Principal Market.</div>
      <div style="text-indent: 99pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Beneficial Ownership Limitation.</u>&#160; Notwithstanding anything to the contrary contained in this Agreement, the Company shall not&#160;issue or sell, and the Investor shall not&#160;purchase
        or acquire, any shares of Common Stock under this Agreement&#160;which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated
        thereunder), would result in the beneficial ownership by the&#160;Investor&#160;of more than&#160;4.99% of the then issued and outstanding shares of Common Stock (the &#8220;<u>Beneficial Ownership Limitation</u>&#8221;). Upon the written or oral request of the Investor, the
        Company shall promptly (but not later than 24 hours) confirm orally or in writing to the Investor the number of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required
        hereby and the application hereof. The Investor&#8217;s written certification to the Company of the applicability of the Beneficial Ownership Limitation, and the resulting effect thereof hereunder at any time, shall be conclusive with respect to the
        applicability thereof and such result absent manifest error.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">INVESTOR&#8217;S REPRESENTATIONS AND WARRANTIES.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Organization, Authority</u>.&#160; Investor is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, with the requisite
        power and authority to enter into and to consummate the transactions contemplated by this Agreement and the Registration Rights Agreement and otherwise to carry out its obligations hereunder and thereunder.</div>
      <div>&#160;<br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-11-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Investment Purpose</u>.&#160; &#160;The Investor is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any
        part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or
        indirect arrangement or understandings with any other Persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
        the Investor&#8217;s right to sell the Securities at any time pursuant to the Registration Statement described herein or otherwise in compliance with applicable federal and state securities laws).&#160;&#160;The Investor is acquiring the Securities hereunder in
        the ordinary course of its business.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Accredited Investor Status</u>.&#160; The Investor is an &#8220;accredited investor&#8221; as that term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Reliance on Exemptions</u>.&#160; The Investor understands that the Securities are being offered and sold to it in reliance on specific exemptions from the registration requirements of
        United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor&#8217;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the
        Investor set forth herein in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Information</u>.&#160; The Investor understands that its investment in the Securities involves a high degree of risk.&#160; The Investor (i) is able to bear the economic risk of an investment
        in the Securities including a total loss thereof, (ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has had an
        opportunity to ask questions of and receive answers from the officers of the Company concerning the financial condition and business of the Company and others matters related to an investment in the Securities.&#160; Neither such inquiries nor any other
        due diligence investigations conducted by the Investor or its representatives shall modify, amend or affect the Investor&#8217;s right to rely on the Company&#8217;s representations and warranties contained in <u>Section 4</u> below.&#160; The Investor has sought
        such accounting, legal and tax advice from its own independent advisors as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Governmental Review</u>.&#160; The Investor understands that no U.S. federal or state agency or any other government or governmental agency has passed on or made any recommendation or
        endorsement of the Securities or the fairness or suitability of an investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Transfer or Sale</u>.&#160; The Investor understands that (i) the Securities may not be offered for sale, sold, assigned or transferred unless (A) registered pursuant to the Securities
        Act or (B) an exemption exists permitting such Securities to be sold, assigned or transferred without such registration; (ii) any sale of the Securities made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and
        further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may
        require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Validity; Enforcement</u>.&#160; This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid and binding agreement of the Investor
        enforceable against the Investor in accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other laws relating to, or affecting
        generally, the enforcement of applicable creditors&#8217; rights and remedies.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Residency</u>.&#160; The Investor is a resident of the State of Illinois.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-12-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Short Selling</u>.&#160; The Investor represents and warrants to the Company that at no time prior to the date of this Agreement has any of the Investor, its agents, representatives or
        affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) &#8220;short sale&#8221; (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes
        a net short position with respect to the Common Stock.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">REPRESENTATIONS AND WARRANTIES OF THE COMPANY.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Company represents and warrants to the Investor that, except as set forth in the disclosure schedules attached hereto, which exceptions shall be deemed to be a part of the representations and
        warranties made hereunder, as of the date hereof and as of the Commencement Date:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Organization and Qualification</u>. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the
        laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted.&#160;&#160;Each of the Company and its Subsidiaries
        is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the
        failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect, and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or
        seeking to revoke, limit or curtail such power and authority or qualification.&#160; The Company has no Subsidiaries required to be disclosed pursuant to Item 601(b)(21)(ii) of Regulation S-K, except as set forth in the Company&#8217;s Annual Report on Form
        10-K for its fiscal year ended December 31, 2022 filed with the SEC on March 20, 2023.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authorization; Enforcement; Validity</u>.&#160; (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, the
        Registration Rights Agreement and each of the other Transaction Documents, and to issue the Securities in accordance with the terms hereof, (ii) the execution and delivery of the Transaction Documents by the Company and the consummation by it of
        the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares (as defined below in <u>Section 5(e)</u>) and the reservation for issuance and the issuance of the Purchase Shares issuable under
        this Agreement, have been duly authorized by the Company&#8217;s Board of Directors and no further consent or authorization is required by the Company, its Board of Directors or its stockholders (except as provided in this Agreement), (iii) each of this
        Agreement and the Registration Rights Agreement has been, and each other Transaction Document shall be on the Commencement Date, duly executed and delivered by the Company and (iv) each of this Agreement and the Registration Rights Agreement
        constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except as such
        enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or other laws relating to, or affecting generally, the enforcement of creditors&#8217; rights and remedies. The
        Board of Directors of the Company has approved the resolutions (the &#8220;<u>Signing Resolutions</u>&#8221;) substantially in the form provided to the Investor to authorize this Agreement, the Registration Rights Agreement and the transactions contemplated
        hereby and thereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any respect.&#160; The Company has delivered to the Investor a true and correct copy of minutes of a meeting of the Board of
        Directors of the Company at which the Signing Resolutions were duly adopted by the Board of Directors or a unanimous written consent adopting the Signing Resolutions executed by all of the members of the Board of Directors of the Company.&#160; Except
        as set forth in this Agreement, no other approvals or consents of the Company&#8217;s Board of Directors, any authorized committee thereof, or stockholders (except as provided in this Agreement) is necessary under applicable laws and the Company&#8217;s
        Certificate of Incorporation or Bylaws to authorize the execution and delivery of the Transaction Documents or any of the transactions contemplated thereby, including, but not limited to, the issuance of the Commitment Shares and the issuance of
        the Purchase Shares.</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-13-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Capitalization</u>.&#160; As of the date hereof, the authorized capital stock of the Company is set forth in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31,
        2022.&#160; Except as disclosed in the SEC Documents (as defined below), (i) no shares of the Company&#8217;s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii)
        there are no outstanding debt securities, (iii) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital
        stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of
        its Subsidiaries or options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries,
        (iv) there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement), (v) there are no
        outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its
        Subsidiaries is or may become bound to redeem a security of the Company or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities
        as described in this Agreement and (vii) the Company does not have any stock appreciation rights or &#8220;phantom stock&#8221; plans or agreements or any similar plan or agreement.&#160; The Company has furnished or made available to the Investor true and correct
        copies of the Company&#8217;s Restated Certificate of Incorporation, as amended and as in effect on the date hereof (the &#8220;<u>Certificate of Incorporation</u>&#8221;), and the Company&#8217;s Amended and Restated Bylaws, as amended and as in effect on the date hereof
        (the &#8220;<u>Bylaws</u>&#8221;), and summaries of the material terms of all securities convertible into or exercisable for Common Stock, if any, and copies of any documents containing the material rights of the holders thereof in respect thereto that are not
        disclosed in the SEC Documents.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Issuance of Securities</u>.&#160; Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the Purchase Shares shall be validly issued, fully paid
        and nonassessable and free from all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.&#160; Upon
        issuance in accordance with the terms and conditions of this Agreement, the Commitment Shares (as defined in <u>Section 5(e)</u>) shall be validly issued, fully paid and nonassessable and free from all taxes, liens, charges, restrictions, rights
        of first refusal and preemptive rights with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. 3,000,000 shares of Common Stock have been duly authorized and reserved for issuance upon
        purchase under this Agreement as Purchase Shares.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-14-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Conflicts</u>.&#160; The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated hereby and
        thereby (including, without limitation, the issuance of the Commitment Shares and the reservation for issuance and issuance of the Purchase Shares) will not (i) result in a violation of the Certificate of Incorporation or the Bylaws or (ii)
        conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or
        instrument to which the Company or any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations, the rules of the Principal Market
        applicable to the Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations,
        cancellations and violations under clause (ii), which would not reasonably be expected to result in a Material Adverse Effect.&#160; Neither the Company nor its Subsidiaries is in violation of any term of or in default under its certificate or articles
        of incorporation, any certificate of designation, preferences and rights of any outstanding series of preferred stock of the Company or bylaws or other organizational documents. <font style="color: rgb(0, 0, 0);">Neither the Company nor any
          Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any
          Subsidiary received written notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties
          is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental authority or (iii) is in violation of any statute, rule, ordinance or
          regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor
          matters, except in each case as would not have or reasonably be expected to result in a Material Adverse Effect.</font> Except as specifically contemplated by this Agreement and as required under the Securities Act or applicable state securities
        laws and the rules of the Principal Market, the Company is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order
        for it to execute, deliver or perform any of its obligations under or contemplated by the Transaction Documents in accordance with the terms hereof or thereof.&#160; Except as set forth elsewhere in this Agreement, all consents, authorizations, orders,
        filings and registrations which the Company is required to obtain pursuant to the preceding sentence shall be obtained or effected on or prior to the Commencement Date.&#160; Except as disclosed in the SEC Documents, since one year prior to the date
        hereof, the Company has not received nor delivered any notices or correspondence from or to the Principal Market, other than notices with respect to listing of additional shares of Common Stock and other routine correspondence. Except as disclosed
        in the SEC Documents, the Principal Market has not commenced any delisting proceedings against the Company.</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>SEC Documents; Financial Statements</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities
        Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve months preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
        materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;<u>SEC Documents</u>&#8221;) on a timely basis or has received a valid extension of such time of filing and has filed
        any such SEC Documents prior to the expiration of any such extension, other than the Company&#8217;s untimely filing of its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, which was filed with the SEC on July 1, 2022.&#160;&#160;As of
        their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.&#160; None of the SEC Documents, when filed, contained any untrue statement of a material fact
        or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. <font style="color: rgb(0, 0, 0);">The
          consolidated financial statements of the Company included or incorporated by reference in the SEC Documents, together with the related notes and schedules, presented fairly, in all material respects, the consolidated financial position of the
          Company as of the dates indicated and the consolidated results of operations, cash flows and changes in stockholders&#8217; equity of the Company for the periods specified and were prepared in compliance in all material respects with the requirements
          of the Securities Act and Exchange Act, as applicable, as in effect as of the time of filing and in conformity with generally accepted accounting principles in the United States as in effect as of the time of filing (&#8220;<u>GAAP</u>&#8221;) applied on a
          consistent basis (except (i)&#160;for such adjustments to accounting standards and practices as are noted therein and (ii)&#160;in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed or summary statements,
          and subject to immaterial year-end audit adjustments) during the periods involved; the other financial and statistical data with respect to the Company contained or incorporated by reference in the SEC Documents, are accurately and fairly
          presented in all material respects and prepared on a basis materially consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or
          incorporated by reference in the SEC Documents that are not included or incorporated by reference as required; the Company does not have any material liabilities or obligations, direct or contingent (including any off balance sheet obligations),
          not described in the SEC Documents (including the exhibits thereto and documents incorporated by reference thereto), which are required to be described in the SEC Documents (including the exhibits thereto and documents incorporated by reference
          thereto); and all disclosures contained or incorporated by reference in the SEC Documents, if any, regarding&#160;&#8220;non-GAAP&#160;financial measures&#8221; (as such term is defined by the rules and regulations of the SEC) comply in all material respects with
          Regulation G of the Exchange Act and Item 10 of Regulation&#160;S-K&#160;under the Securities Act, to the extent applicable.</font> T<font style="color: rgb(0, 0, 0);">he Company does not have pending before the SEC any request for confidential treatment
          of information.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-15-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Absence of Certain Changes; No Undisclosed Events, Liabilities or Developments; Solvency</u>.&#160; Except as disclosed in the SEC Documents, since December 31, 2022, <font style="color: rgb(0, 0, 0);">there has been no event, occurrence or development that has had or that would reasonably be expected to result in a Material Adverse Effect, and there has been no material adverse change in the business, properties, operations,
          financial condition or results of operations of the Company or its Subsidiaries, taken as a whole.&#160; Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has
          occurred or exists with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that is required to be disclosed by the Company under applicable securities laws
          at the time this representation is made that has not been publicly disclosed at least one (1) Business Day prior to the date that this representation is made</font>. The Company has not taken any steps, and does not currently expect to take any
        steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy<font style="font-weight: bold;">&#160;</font>or
        insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Absence of Litigation</u>. <font style="color: rgb(0, 0, 0);">Except as disclosed in the SEC Documents, there is no action, suit, inquiry, notice of violation, proceeding, or
          investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
          authority (federal, state, county, local or foreign) (collectively, an &#8220;<u>Action</u>&#8221;), which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) would, if
          there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.</font>&#160;<font style="color: rgb(0, 0, 0);">Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the
          subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which would, if there were an unfavorable decision, have or reasonably be expected to result in a
          Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer of the Company.&#160; The SEC has
          not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-16-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Acknowledgment Regarding Investor&#8217;s Status</u>.&#160; The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm&#8217;s length purchaser with respect to the
        Transaction Documents and the transactions contemplated hereby and thereby.&#160; The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the
        Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and
        thereby is merely incidental to the Investor&#8217;s purchase of the Securities.&#160; The Company further represents to the Investor that the Company&#8217;s decision to enter into the Transaction Documents has been based solely on the independent evaluation by
        the Company and its representatives and advisors.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No General Solicitation; No Integrated Offering</u>.&#160; Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has engaged in any form of general
        solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Securities contemplated hereby. Neither the Company, nor or any of its affiliates, nor any Person acting
        on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the offer and sale of any of the Securities under the
        Securities Act, whether through integration with prior offerings or otherwise, or cause this offering of the Securities to be integrated with prior offerings by the Company in a manner that would require stockholder approval pursuant to the rules
        of the Principal Market. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Market.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Intellectual Property Rights</u>. <font style="color: rgb(0, 0, 0);">The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
          trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as
          described in the SEC Documents and which the failure to so have would reasonably be expected to have a Material Adverse Effect (collectively, the &#8220;<u>Intellectual Property Rights</u>&#8221;).&#160; None of, and neither the Company nor any Subsidiary has
          received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.&#160;
          Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC Documents, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights
          violate or infringe upon the rights of any Person, except as would not have or reasonably be expected to not have a Material Adverse Effect.&#160; To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no
          existing infringement by another Person of any of the Intellectual Property Rights.&#160; The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual
          properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Environmental Laws</u>.&#160; <font style="color: rgb(0, 0, 0);">The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
          pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
          pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#8220;<u>Hazardous Materials</u>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal,
          transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered,
          promulgated or approved thereunder (&#8220;<u>Environmental Laws</u>&#8221;); (ii)&#160;have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance
          with all terms and conditions of any such permit, license or approval, except where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-17-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Title</u>.&#160; Except as set forth in the SEC Documents, the Company and its Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and
        marketable title in all personal property owned by them that is material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects (&#8220;<u>Liens</u>&#8221;) and, except for Liens as do not
        materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of
        which is neither delinquent nor subject to penalties.&#160;&#160;Any real property and facilities held under lease by the Company and its Subsidiaries are held by them under valid, subsisting and, to the knowledge of the Company, enforceable leases with
        which the Company and its Subsidiaries are in compliance with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Insurance</u>.&#160; The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as
        management of the Company believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged.&#160; Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and
        neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to
        continue its business at a cost that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations of the Company and its Subsidiaries, taken as a whole.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Regulatory Permits</u>. <font style="color: rgb(0, 0, 0);">The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
          state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Documents, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse
          Effect (&#8220;<u>Material Permits</u>&#8221;), and neither the Company nor any Subsidiary has received any notice of any Proceeding relating to the revocation or modification of any Material Permit. For all purposes of this Agreement, the term &#8220;<u>Proceeding</u>&#8221;
          means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Tax Status</u>.&#160; <font style="color: rgb(0, 0, 0);">Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material
          Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is
          subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except for taxes, if any, as are being contested in good faith
          and as to which adequate reserves have been established by the Company and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports
          or declarations apply.&#160; There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Transactions With Affiliates and Employees</u>.&#160; &#160;<font style="color: rgb(0, 0, 0);">Except as disclosed in the SEC Documents, none of the officers or directors of the Company or any
          Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
          including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise
          requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
          member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including
          stock option agreements under any stock option plan of the Company</font>.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-18-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Application of Takeover Protections</u>.&#160; The Company and its board of directors have taken or will take prior to the Commencement Date all necessary action, if any, in order to
        render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of
        its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company&#8217;s issuance of the Securities and the Investor&#8217;s ownership of the
        Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Disclosure</u>.&#160;&#160;Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents that will be timely publicly disclosed by the
        Company, the Company confirms that neither it nor any other Person authorized to act on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public
        information which is not otherwise disclosed in the SEC Documents.&#160;&#160;&#160;The Company understands and confirms that the Investor will rely on the foregoing representation in effecting purchases and sales of securities of the Company.&#160;&#160;All of the
        disclosure furnished by or on behalf of the Company by a Person authorized by the Company to the Investor regarding the Company, its business and the transactions contemplated hereby is true and correct in all material respects and does not contain
        any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The press releases disseminated by the
        Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
        statements therein, in light of the circumstances under which they were made and at the time when made, not misleading.&#160;&#160;The Company acknowledges and agrees that the Investor neither makes nor has made any representations or warranties with respect
        to the transactions contemplated hereby other than those specifically set forth in <u>Section 3</u> hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Foreign Corrupt Practices</u>. <font style="color: rgb(0, 0, 0);">Neither the Company nor any Subsidiary has, and to the Company&#8217;s knowledge, no agent or other person acting on
          behalf of the Company and each Subsidiary has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment
          to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company and each Subsidiary (or made by any
          person acting on behalf of the Company and each Subsidiary of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>DTC Eligibility</u>.&#160; The Company, through the Transfer Agent, currently participates in the DTC Fast Automated Securities Transfer (FAST) Program and the Common Stock can be
        transferred electronically to third parties via the DTC Fast Automated Securities Transfer (FAST) Program.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-19-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Sarbanes-Oxley Act; Internal Controls</u>. <font style="color: rgb(0, 0, 0);">The Company and the Subsidiaries are in compliance in all material respects with all applicable
          requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof.&#160;&#160;Except as disclosed in the SEC
          Documents, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii)
          transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&#8217;s general or specific
          authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in the SEC Documents, the Company and
          the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
          required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms.&#160; The Company&#8217;s certifying officers
          evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation Date</u>&#8221;).&#160;






          The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
          Date. Except as disclosed in the Company&#8217;s most recently filed period report under the Exchange Act, since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
          Act) of the Company and its Subsidiaries that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Certain Fees</u>. No brokerage or finder&#8217;s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent,
        investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Investor shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons
        for fees of a type contemplated in this <u>Section 4(w)</u> that may be due in connection with the transactions contemplated by the Transaction Documents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Investment Company</u>. <font style="color: rgb(0, 0, 0);">Neither the Company or its Subsidiaries is or, after giving effect to the offering and sale of the Securities to the
          Investor pursuant to this Agreement, will be, required to be registered as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company,&#8221; as such terms are defined in the Investment Company Act of 1940, as amended.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Listing and Maintenance Requirements</u>. The Common Stock is registered pursuant to Section&#160;12(b) of the Exchange Act, and the Company has taken no action designed to, or which to
        its knowledge is likely to have the effect of, terminating the registration of the Common Stock pursuant to the Exchange Act nor has the Company received any notification that the SEC is currently contemplating terminating such registration. The
        issued and outstanding shares of Common Stock are listed and admitted for trading on the Principal Market, and the Company is in compliance in all material respects with the current listing requirements of the Principal Market; and the Securities
        will be listed and admitted for trading on the Principal Market at or prior to Commencement, with respect to the Commitment Shares, and prior to the time of sale to the Investor pursuant to this Agreement, with respect to the Purchase Shares.
        Except as disclosed in the SEC Documents, the Company has not, in the twelve (12) months preceding the date hereof, received any notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance
        requirements of the Principal Market. Except as disclosed in the SEC Documents, the Company is, and currently has no reason to believe that it will not in the reasonably foreseeable future continue to be, in compliance with all such listing and
        maintenance requirements.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Accountants</u>.&#160; <font style="color: rgb(0, 0, 0);">As of the Closing Date, the Company&#8217;s accounting firm is Grant Thornton LLP, whose report on the consolidated financial
          statements of the Company is filed with the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2022,&#160;which was filed with the SEC on March 20, 2023.&#160; To the knowledge and belief of the Company, such accounting firm is a
          registered public accounting firm as required by the Exchange Act.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-20-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160; <u>No Market Manipulation</u>.&#160;The Company has not, and to its knowledge no Person acting on its behalf has, (i)&#160;taken, directly or indirectly, any action designed to cause or to result
        in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii)&#160;sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
        or (iii)&#160;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160; <u>Shell Company Status</u>. The Company is not currently, and to its knowledge has never been, an issuer identified in Rule 144(i)(1) under the Securities Act.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(cc)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Office of Foreign Assets Control</u>.&#160; Neither the Company nor any Subsidiary nor, to the Company&#8217;s
          knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(dd)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>U.S. Real Property Holding Corporation</u>.&#160; The Company is not and has never been a U.S. real property
          holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended.&#160;</font></div>
      <div>&#160;</div>
      <div>
        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">(ee)&#160;&#160;&#160;&#160;&#160;&#160; <u>Bank Holding Company Act</u>.&#160; Neither the Company nor any of its Subsidiaries or affiliates is subject to the Bank Holding Company Act of 1956, as amended
          (the &#8220;<u>BHCA</u>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<u>Federal Reserve</u>&#8221;).&#160; Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly or indirectly, five percent
          (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.&#160; Neither the Company nor any
          of its Subsidiaries or affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ff)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Money Laundering</u>.&#160;&#160;The operations of the Company and its Subsidiaries are and have been conducted
            at all times in compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations
            thereunder (collectively, the &#8220;<u>Money Laundering Laws</u>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money
            Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</font></div>
      </div>
      <div>
        <div style="color: rgb(0, 0, 0);">&#160;</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(gg)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Labor Matters</u>.&#160;&#160;No labor dispute exists or, to the knowledge of the Company, is imminent with respect
          to any of the employees of the Company, which would reasonably be expected to result in a Material Adverse Effect.&#160; None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the
          Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good.&#160; To the
          knowledge of the Company, no executive officer of the Company or any Subsidiary is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or
          non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any
          liability with respect to any of the foregoing matters.&#160; The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions
          of employment and wages and hours, except where the failure to be in compliance would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-21-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(hh)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Cybersecurity</u>. (i)(x) To the Company&#8217;s knowledge,&#160;there has been no security breach or other
          compromise of or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third
          party data maintained by or on behalf of it), equipment or technology (collectively, &#8220;<u>IT Systems and Data</u>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would
          reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes and all applicable judgments, orders,
          rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data
          from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
          maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries
          have implemented backup and disaster recovery technology consistent with customary industry standards and practices.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(kk)&#160;&#160;&#160;&#160;&#160;&#160; <u>Smaller Reporting Company Status</u>. As of the date hereof, the Company is, and as of the Commencement Date, the Company believes in good faith that it will be, a &#8220;smaller reporting
        company&#8221; as defined in Rule 12b-2 of the Exchange Act.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160; <u>No Disqualification Events</u>.&#160; None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in
        the offering contemplated hereby, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act)
        connected with the Company in any capacity at the time of sale (each, an &#8220;<u>Issuer Covered Person</u>&#8221;) is subject to any of the &#8220;Bad Actor&#8221; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &#8220;<u>Disqualification







          Event</u>&#8221;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-weight: bold;">COVENANTS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Filing of Current Report and Registration Statement</u>.&#160; The Company agrees that it shall, within the time required under the Exchange Act, file with the SEC a report on Form 8-K
        relating to the transactions contemplated by, and describing the material terms and conditions of, this Agreement and the Registration Rights Agreement (the &#8220;<u>Current Report</u>&#8221;). The Company shall also file with the SEC, within ten (10)
        Business Days from the date hereof, a new registration statement on Form S-1 (the &#8220;<u>Registration Statement</u>&#8221;) covering only the resale of the Purchase Shares and all of the Commitment Shares, in accordance with the terms of the Registration
        Rights Agreement between the Company and the Investor, dated as of the date hereof (the &#8220;<u>Registration Rights Agreement</u>&#8221;). The Company shall permit the Investor to review and comment upon (1)&#160;the final pre-filing draft version of the Current
        Report at least two (2) Business Days prior to its filing with the SEC, and the Company shall give due consideration to all such comments. The Investor shall use its reasonable best efforts to comment upon the Current Report within one (1)&#160;Business
        Day from the date the Investor receives the final version thereof from the Company. The Investor shall cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of the Current Report and the
        Registration Statement with the SEC.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-22-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Blue Sky</u>. The Company shall take all such action, if any, as is reasonably necessary in order to obtain an exemption for or to register or qualify (i) the issuance of the
        Commitment Shares and the sale of the Purchase Shares to the Investor under this Agreement and (ii) any subsequent resale of all Commitment Shares and all Purchase Shares by the Investor, in each case, under applicable securities or &#8220;Blue Sky&#8221; laws
        of the states of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence of any such action so taken to the Investor.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Listing/DTC</u>.&#160; The Company shall promptly secure the listing of all of the Purchase Shares and Commitment Shares to be issued to the Investor hereunder on the Principal Market
        (subject to official notice of issuance) and upon each other national securities exchange or automated quotation system, if any, upon which the Common Stock is then listed, and shall use commercially reasonable efforts to maintain, so long as any
        shares of Common Stock shall be so listed, such listing of all such Securities from time to time issuable hereunder. The Company shall use commercially reasonable efforts to maintain the listing of the Common Stock on the Principal Market and shall
        comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules and regulations of the Principal Market. Neither the Company nor any of its Subsidiaries shall take any action that would reasonably be
        expected to result in the delisting or suspension of the Common Stock on the Principal Market.&#160; The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it receives from any
        Person regarding the continued eligibility of the Common Stock for listing on the Principal Market; provided, however, that the Company shall not be required to provide the Investor copies of any such notice that the Company reasonably believes
        constitutes material non-public information and the Company would not be required to publicly disclose such notice in any report or statement filed with the SEC and under the Exchange Act or the Securities Act. The Company shall pay all fees and
        expenses in connection with satisfying its obligations under this <u>Section 5(c)</u>.&#160; The Company shall take all commercially reasonable action necessary to ensure that its Common Stock can be transferred electronically as DWAC Shares.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Prohibition of Short Sales and Hedging Transactions</u>.&#160; The Investor agrees that beginning on the date of this Agreement and ending on the date of termination of this Agreement as
        provided in Section 11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any (i) &#8220;short sale&#8221; (as such term is defined in Rule 200 of Regulation SHO of the
        Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Issuance of Commitment Shares</u>.&#160; In consideration for the Investor&#8217;s execution and delivery of this Agreement, the Company shall cause to be issued to the Investor, not later than
        one (1) Business Day after the date hereof, a total of 73,659 shares of Common Stock (the &#8220;<u>Commitment Shares</u>&#8221;) and shall, on the date hereof, deliver to the Transfer Agent the Irrevocable Transfer Agent Instructions with respect to the
        issuance of such Commitment Shares. For the avoidance of doubt, all of the Commitment Shares shall be fully earned as of the date of this Agreement, whether or not the Commencement shall occur or any Purchase Shares are purchased by the Investor
        under this Agreement and irrespective of any subsequent termination of this Agreement.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-23-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Due Diligence; Non-Public Information</u>.&#160; The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate and upon reasonable advance notice to
        the Company, to perform reasonable due diligence on the Company during normal business hours.&#160; The Company and its officers and employees shall provide information and reasonably cooperate with the Investor in connection with any reasonable request
        by the Investor related to the Investor&#8217;s due diligence of the Company.&#160; Each party hereto agrees not to disclose any Confidential Information of the other party to any third party and shall not use the Confidential Information for any purpose
        other than in connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the Confidential Information shall remain the property of the disclosing party and agrees that it shall take all
        reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any
        information that constitutes or might constitute material, non-public information, unless a simultaneous public announcement thereof is made by the Company in the manner contemplated by Regulation FD. In the event of a breach of the foregoing
        covenant by the Company or any Person acting on its behalf (as determined in the reasonable good faith judgment of the Investor), in addition to any other remedy provided herein or in the other Transaction Documents, if the Investor is holding any
        Securities at the time of the disclosure of material, non-public information, the Investor shall have the right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information
        without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has received information that constitutes material, non-public information, the Company shall have at least one (1)
        Business Day to publicly disclose such material, non-public information prior to any such disclosure by the Investor, the Company shall have failed to demonstrate to the Investor in writing within such time period that such information does not
        constitute material, non-public information, and the Company shall have failed to publicly disclose such material, non-public information within such time period. The Investor shall not have any liability to the Company, any of its Subsidiaries, or
        any of their respective directors, officers, employees, stockholders or agents, for any such disclosure. The Company understands and confirms that the Investor shall be relying on the foregoing covenants in effecting transactions in securities of
        the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Purchase Records</u>. The Investor and the Company shall each maintain records showing the remaining Available Amount at any given time and the dates and Purchase Amounts for each
        Regular Purchase, Accelerated Purchase and Additional Accelerated Purchase or shall use such other method, reasonably satisfactory to the Investor and the Company.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Taxes.</u> The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of any shares of Common Stock to the
        Investor made under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Use of Proceeds</u>. The Company will use the net proceeds from the offering as described in the Registration Statement or the SEC Documents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Other Transactions</u>. The Company shall not enter into, announce or recommend to its stockholders any agreement, plan, arrangement or transaction in or of which the terms thereof
        would restrict, materially delay, conflict with or impair the ability or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the Company to deliver the Purchase Shares
        and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Integration</u>.&#160; From and after the date of this Agreement, neither the Company, nor or any of its affiliates will, and the Company shall use its reasonable best efforts to ensure
        that no Person acting on their behalf will, directly or indirectly, make any offers or sales of any security or solicit any offers to buy any security, under circumstances that would (i) require registration of the offer and sale by the Company to
        the Investor of any of the Securities under the Securities Act, or (ii) cause this offering of the Securities by the Company to the Investor to be integrated with other offerings by the Company in a manner that would require stockholder approval
        pursuant to the rules of the Principal Market, unless in the case of this clause (ii), stockholder approval is obtained before the closing of such subsequent transaction in accordance with the rules of such Principal Market.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-24-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Limitation on Similar Transactions.</u>&#160; From and after the date of this Agreement until the earlier of (i) the ninety-first (91<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>) calendar day after the effective date of any termination of this Agreement under subsection (a), (b), (c) or (d) of <u>Section 11</u> hereof and (ii) the later of (A) the 24-month anniversary of the date of this
        Agreement and (B) the Maturity Date (if the Commencement has occurred), the Company and its Subsidiaries shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common
        Stock or Common Stock Equivalents (or any combination of units thereof) in any &#8220;equity line of credit&#8221;, &#8220;at-the-market offering&#8221; or other similar offering in which the Company may offer, issue or sell Common Stock or Common Stock Equivalents (or
        any combination of units thereof) at a future determined price, other than in connection with an Exempt Issuance. The Investor shall be entitled to seek injunctive relief against the Company and its Subsidiaries to preclude any such issuance, which
        remedy shall be in addition to any right to collect damages, without the necessity of showing economic loss and without any bond or other security being required. &#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or its
        Subsidiaries which entitle the holder thereof to acquire at any time shares of Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable
        or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock. &#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a) any Securities issued or issuable to the Investor pursuant to this Agreement, and any securities,
        including, without limitation, Common Stock or Common Stock Equivalents (or any combination of units thereof), issued or issuable to the Investor or any affiliate of the Investor pursuant to any other existing agreement or arrangement between the
        Company or any of its Subsidiaries, on the one hand, and the Investor or any of its affiliates, on the other hand, if any, (b) any securities issued or issuable upon the exercise or exchange of or conversion of any shares of Common Stock or Common
        Stock Equivalents owned or held, directly or indirectly, by the Investor or any of its affiliates or designees at any time, (c) any securities, including, without limitation, Common Stock or Common Stock Equivalents (or any combination of units
        thereof), issuable to the Investor or any of its affiliates or designees pursuant to any other future agreement or arrangement between the Investor or any of its affiliates or designees, on the one hand, and the Company or any of its Subsidiaries,
        on the other hand, entered into after the date of this Agreement, if any, or (d) shares of Common Stock issued pursuant to an &#8220;at-the-market offering&#8221; under Rule 415(a)(4) under the Securities Act by the Company exclusively through one or more
        registered broker-dealer(s) acting as agent(s) of the Company pursuant to a written agreement between the Company and such registered broker-dealer(s) only.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">TRANSFER AGENT INSTRUCTIONS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the date of this Agreement, the Company shall issue irrevocable instructions to the Transfer Agent substantially in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit







            C</u></font> to issue the Commitment Shares in accordance with the terms of this Agreement (the &#8220;<u>Irrevocable Transfer Agent Instructions</u>&#8221;). The certificate(s) or book-entry statement(s) representing the Commitment Shares, except as set
        forth below, shall bear the following restrictive legend (the &#8220;<u>Restrictive Legend</u>&#8221;):</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-right: 36pt; margin-left: 36pt; font-weight: bold;">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
        SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
        SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER&#8217;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-25-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the earlier of (i) the Commencement Date and (ii) such time that the Investor shall request, provided all conditions of Rule 144 under the Securities Act are met, the Company shall,
        no later than two (2) Business Days following the delivery by the Investor to the Company or the Transfer Agent of one or more legended certificates or book-entry statements representing the Commitment Shares (which certificates or book-entry
        statements the Investor shall promptly deliver on or prior to the first to occur of the events described in clauses (i) and (ii) of this sentence), as directed by the Investor, issue and deliver (or cause to be issued and delivered) to the
        Investor, as requested by the Investor, either: (A) a certificate or book-entry statement representing such Commitment Shares that is free from all restrictive and other legends or (B) a number of shares of Common Stock equal to the number of
        Commitment Shares represented by the certificate(s) or book-entry statement(s) so delivered by the Investor as DWAC Shares.&#160; The Company shall take all actions to carry out the intent and accomplish the purposes of the immediately preceding
        sentence, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the Transfer Agent, and any successor transfer agent of the Company, as may be reasonably requested from time to
        time by the Investor or necessary or desirable to carry out the intent and accomplish the purposes of the immediately preceding sentence. On the Commencement Date, the Company shall issue to the Transfer Agent, or any subsequent transfer agent, (i)
        irrevocable instructions in the form substantially similar to those used by the Investor in substantially similar transactions (the &#8220;<u>Commencement Irrevocable Transfer Agent Instructions</u>&#8221;) and (ii) the notice of effectiveness of the
        Registration Statement in the form attached as an exhibit to the Registration Rights Agreement (the &#8220;<u>Notice of Effectiveness of Registration Statement</u>&#8221;), in each case to issue the Commitment Shares and the Purchase Shares in accordance with
        the terms of this Agreement and the Registration Rights Agreement. All Purchase Shares and Commitment Shares to be issued from and after Commencement to or for the benefit of the Investor pursuant to this Agreement shall be issued only as DWAC
        Shares. The Company represents and warrants to the Investor that, while this Agreement is effective, no instruction other than the Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement
        referred to in this <u>Section 6(b)</u> will be given by the Company to the Transfer Agent with respect to the Purchase Shares or the Commitment Shares from and after Commencement, and the Purchase Shares and the Commitment Shares covered by the
        Registration Statement shall otherwise be freely transferable on the books and records of the Company. If the Investor effects a sale, assignment or transfer of the Purchase Shares, the Company shall permit the transfer and shall promptly instruct
        the Transfer Agent (and any subsequent transfer agent) to issue DWAC Shares in such name and in such denominations as specified by the Investor to effect such sale, transfer or assignment. The Company acknowledges that a breach by it of its
        obligations hereunder will cause irreparable harm to the Investor. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this <u>Section 6 </u>will be inadequate and agrees, in the event of a breach or
        threatened breach by the Company of the provisions of this <u>Section 6</u>, that the Investor shall be entitled, in addition to all other available remedies, to seek an order and/or injunction restraining any breach and requiring immediate
        issuance and transfer, without the necessity of showing economic loss and without any bond or other security being required. The Company agrees that if the Company fails to fully comply with the provisions of this <u>Section 6(b)</u> within five
        (5) Business Days of the Investor providing the deliveries referred to above, the Company shall, at the Investor&#8217;s written instruction, purchase such shares of Common Stock containing the restrictive legend from the Investor at the greater of the
        (i) purchase price paid for such shares of Common Stock (as applicable) and (ii) the Closing Sale Price of the Common Stock on the date of the Investor&#8217;s written instruction.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-26-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z07b5365bec984ec8bfe26366a7e567da" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">7.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">CONDITIONS TO THE COMPANY&#8217;S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-weight: bold;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The right of the Company hereunder to commence sales of the Purchase Shares on the Commencement Date is subject to the satisfaction of each of the following conditions:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Investor shall have executed each of the Transaction Documents and delivered the same to the Company;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Registration Statement covering the resale of the Purchase Shares and all of the Commitment Shares shall have been declared effective under the Securities Act by the SEC, and no stop
        order with respect to the Registration Statement shall be pending or threatened by the SEC; and&#160;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The representations and warranties of the Investor shall be true and correct in all material respects as of the date hereof and as of the Commencement Date as though made at that time.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zdaaf86430a864e9085b9e1f9fe7bb68d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-weight: bold;">8.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">CONDITIONS TO THE INVESTOR&#8217;S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The obligation of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction of each of the following conditions on or prior to the Commencement Date and, once such
        conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have executed each of the Transaction Documents and delivered the same to the Investor;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have issued or caused to be issued to the Investor (i) one or more certificates or book-entry statements representing the Commitment Shares free from all restrictive
        and other legends or (ii) a number of shares of Common Stock equal to the number of Commitment Shares as DWAC Shares, in each case in accordance with <u>Section 6(b)</u>;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Common Stock shall be listed or quoted on the Principal Market, subject only to customary listing conditions, trading in the Common Stock shall not have been within the last 365 days
        suspended by the SEC or the Principal Market, and all Securities to be issued by the Company to the Investor pursuant to this Agreement shall have been approved for listing or quotation on the Principal Market in accordance with the applicable
        rules and regulations of the Principal Market, subject only to official notice of issuance and any standard listing conditions for transactions of this nature;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Investor shall have received the opinions and negative assurances of the Company&#8217;s legal counsel, dated as of the Commencement Date, substantially in the forms heretofore agreed by
        the parties hereto;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The representations and warranties of the Company shall be true and correct in all material respects (except to the extent that any of such representations and warranties is already
        qualified as to materiality in Section 4 above, in which case, the portion of such representations and warranties so qualified shall be true and correct without further qualification) as of the date hereof and as of the Commencement Date as though
        made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied in all material respects with the
        covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date.&#160; The Investor shall have received a certificate, executed by the CEO,
        President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit A</u></font>;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-27-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Board of Directors of the Company shall have adopted resolutions approving the transactions contemplated hereby, which resolutions shall be in full force and effect without any
        amendment or supplement thereto as of the Commencement Date;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of the Commencement Date, the Company shall have reserved out of its authorized and unissued Common Stock, solely for the purpose of effecting purchases of Purchase Shares hereunder,
        3,000,000 shares of Common Stock;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Commencement Irrevocable Transfer Agent Instructions and the Notice of Effectiveness of Registration Statement each shall have been delivered to and acknowledged in writing (email
        being sufficient) by the Company and the Company&#8217;s Transfer Agent (or any successor transfer agent);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in the State of Delaware issued by the Secretary of State of
        the State of Delaware as of a date within ten (10) Business Days of the Commencement Date;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have delivered to the Investor a certified copy of the Certificate of Incorporation as certified by the Secretary of State of the State of Delaware within ten (10)
        Business Days of the Commencement Date;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall have delivered to the Investor a secretary&#8217;s certificate executed by the Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit B</u></font>;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Registration Statement covering the resale of the Purchase Shares and all of the Commitment Shares shall have been declared effective under the Securities Act by the SEC, and no stop
        order with respect to the Registration Statement shall be pending or threatened by the SEC. The Company shall have prepared and filed with the SEC, not later than one (1) Business Day after the effective date of the Registration Statement, a final
        and complete prospectus (the preliminary form of which shall be included in the Registration Statement) and shall have delivered to the Investor a true and complete copy thereof. Such prospectus shall be current and available for the resale by the
        Investor of all of the Securities covered thereby. The Current Report shall have been filed with the SEC as required pursuant to <u>Section 5(a)</u>. All reports, schedules, registrations, forms, statements, information and other documents
        required to have been filed by the Company with the SEC at or prior to the Commencement Date pursuant to the reporting requirements of the Exchange Act shall have been filed with the SEC under the Exchange Act;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No Suspension Event has occurred, or any event which, after notice and/or lapse of time, would become a Suspension Event has occurred;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160; All federal, state and local governmental laws, rules and regulations applicable to the transactions contemplated by the Transaction Documents and necessary for the execution, delivery
        and performance of the Transaction Documents and the consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been complied with, and all consents, authorizations and orders of, and all filings and
        registrations with, all federal, state and local courts or governmental agencies and all federal, state and local regulatory or self-regulatory agencies necessary for the execution, delivery and performance of the Transaction Documents and the
        consummation of the transactions contemplated thereby in accordance with the terms thereof shall have been obtained or made, including, without limitation, in each case those required under the Securities Act, the Exchange Act, applicable state
        securities or &#8220;Blue Sky&#8221; laws or applicable rules and regulations of the Principal Market, or otherwise required by the SEC, the Principal Market or any state securities regulators;</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-28-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No statute, regulation, order, decree, writ, ruling or injunction shall have been enacted, entered, promulgated, threatened or endorsed by any federal, state or local court or
        governmental authority of competent jurisdiction which prohibits the consummation of or which would materially modify or delay any of the transactions contemplated by the Transaction Documents; and</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No action, suit or proceeding before any federal, state, local or foreign arbitrator or any court or governmental authority of competent jurisdiction shall have been commenced or
        threatened, and no inquiry or investigation by any federal, state, local or foreign governmental authority of competent jurisdiction shall have been commenced or threatened, against the Company, or any of the officers, directors or affiliates of
        the Company, seeking to restrain, prevent or change the transactions contemplated by the Transaction Documents, or seeking material damages in connection with such transactions.</div>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; margin-left: 36pt;">9. &#160; &#160; &#160; &#160;&#160; INDEMNIFICATION.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In consideration of the Investor&#8217;s execution and delivery of the Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company&#8217;s other obligations under the
        Transaction Documents, the Company shall defend, protect, indemnify and hold harmless the Investor and all of its affiliates, stockholders, members, officers, directors, employees and direct and indirect and any of the foregoing Person&#8217;s agents or
        other representatives (including, without limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the &#8220;<u>Indemnitees</u>&#8221;) from and against any and all actions, causes of action, suits, claims,
        losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys&#8217;
        fees and disbursements (the &#8220;<u>Indemnified Liabilities</u>&#8221;), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction
        Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or
        document contemplated hereby or thereby, or (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction Documents or any
        other certificate, instrument or&#160; document contemplated hereby or thereby, other than, in the case of clause (c), with respect to Indemnified Liabilities which directly and primarily result from the fraud, gross negligence or willful misconduct of
        an Indemnitee. The indemnity in this Section 9 shall not apply to amounts paid in settlement of any claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned
        or delayed. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible
        under applicable law.&#160; Payment under this indemnification shall be made within thirty (30) days from the date the Investor makes written request for it. A certificate containing reasonable detail as to the amount of such indemnification submitted
        to the Company by the Investor shall be conclusive evidence, absent manifest error, of the amount due from the Company to the Investor. If any action shall be brought against any Indemnitee in respect of which indemnity may be sought pursuant to
        this Agreement, such Indemnitee shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Indemnitee. Any Indemnitee shall have the
        right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnitee, except to the extent that (i)&#160;the employment thereof has been
        specifically authorized by the Company in writing, (ii)&#160;the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)&#160;in such action there is, in the reasonable opinion of such separate counsel, a
        material conflict on any material issue between the position of the Company and the position of such Indemnitee, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-29-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">SUSPENSION EVENTS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">A &#8220;<u>Suspension Event</u>&#8221; shall be deemed to have occurred at any time as any of the following events occurs:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the effectiveness of a registration statement registering the resale of the Securities lapses for any reason (including, without limitation, the issuance of a stop order or similar
        order) or such registration statement (or the prospectus forming a part thereof) is unavailable to the Investor for resale of any or all of the Securities to be issued to the Investor under the Transaction Documents, and such lapse or
        unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30) Business Days in any 365-day period, but excluding a lapse or unavailability where (i) the Company terminates a registration
        statement after the Investor has confirmed in writing that all of the Securities covered thereby have been resold or (ii) the Company supersedes one registration statement with another registration statement, including (without limitation) by
        terminating a prior registration statement when it is effectively replaced with a new registration statement covering Securities (provided in the case of this clause (ii) that all of the Securities covered by the superseded (or terminated)
        registration statement that have not theretofore been resold are included in the superseding (or new) registration statement);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the suspension of the Common Stock from trading on the Principal Market for a period of one (1) Business Day, provided that the Company may not direct the Investor to purchase any shares
        of Common Stock during any such suspension;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the delisting of the Common Stock from The Nasdaq Capital Market (or any nationally recognized successor thereto), unless the Common Stock is then immediately thereafter trading on The
        Nasdaq Global Market, The Nasdaq Global Select Market, the New York Stock Exchange, the NYSE American, the NYSE Arca, or the OTCQX or OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized successors thereto);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the failure for any reason by the Transfer Agent to issue Purchase Shares to the Investor within two (2) Business Days after the Purchase Date, Accelerated Purchase Date or Additional
        Accelerated Purchase Date, as applicable, on which the Investor is entitled to receive such Purchase Shares;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Company breaches any representation, warranty, covenant or other term or condition under any Transaction Document if such breach would reasonably be expected to have a Material
        Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach continues for a period of at least five (5) Business Days;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; if any Person commences a proceeding against the Company pursuant to or within the meaning of any Bankruptcy Law;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; if the Company, pursuant to or within the meaning of any Bankruptcy Law, (i) commences a voluntary case, (ii) consents to the entry of an order for relief against it in an involuntary
        case, (iii) consents to the appointment of a Custodian of it or for all or substantially all of its property, or (iv) makes a general assignment for the benefit of its creditors or is generally unable to pay its debts as the same become due;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-30-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (i) is for relief against the Company in an involuntary case, (ii) appoints a Custodian of the
        Company or for all or substantially all of its property, or (iii) orders the liquidation of the Company or any Subsidiary;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; if at any time the Company is not eligible to transfer its Common Stock electronically as DWAC Shares; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; if at any time after the Commencement Date, the Exchange Cap is reached (to the extent such Exchange Cap is applicable pursuant to <u>Section 2(e)</u> hereof), and the stockholder
        approval referred to in <u>Section 2(e)(i)</u> has not been obtained in accordance with the applicable rules of The Nasdaq Stock Market.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">In addition to any other rights and remedies under applicable law and this Agreement, so long as a Suspension Event has occurred and is continuing, or if any event which, after notice and/or lapse of time, would
        reasonably be expected to become a Suspension Event has occurred and is continuing, the Company shall not deliver to the Investor any Regular Purchase Notice, Accelerated Purchase Notice or Additional Accelerated Purchase Notice.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">TERMINATION</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This Agreement may be terminated only as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company which is not discharged within
        90 days, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors (any of which would be a Suspension Event as described in <u>Sections
          10(f)</u>, <u>10(g)</u> and <u>10(h)</u> hereof), this Agreement shall automatically terminate without any liability or payment to the Company (except as set forth below) without further action or notice by any Person.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that (i) the Company fails to file the Registration Statement with the SEC within the period specified in <u>Section 5(a)</u> hereof in accordance with the terms of the
        Registration Rights Agreement or (ii) the Commencement shall not have occurred on or before August 31, 2023, due to the failure to satisfy the conditions set forth in <u>Sections 7</u> and <u>8</u> above with respect to the Commencement, then, in
        the case of clause (i) above, this Agreement may be terminated by the Investor at any time prior to the filing of the Registration Statement and, in the case of clause (ii) above, this Agreement may be terminated by either party at the close of
        business on August 31, 2023 or thereafter, in each case without liability of such party to the other party (except as set forth below); provided, however, that the right to terminate this Agreement under this <u>Section 11(b)</u> shall not be
        available to any party if such party is then in breach of any covenant or agreement contained in this Agreement or any representation or warranty of such party contained in this Agreement fails to be true and correct such that the conditions set
        forth in <u>Section 7(c)</u> or <u>Section 8(e)</u>, as applicable, could not then be satisfied.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for any reason or for no reason by delivering notice (a &#8220;<u>Company Termination
          Notice</u>&#8221;) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).&#160; The Company Termination Notice shall not be effective until one
        (1) Business Day after it has been received by the Investor.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement shall automatically terminate on the date that the Company sells and the Investor purchases the full Available Amount as provided herein, without any action or notice on
        the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-31-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; If, for any reason or for no reason, the full Available Amount has not been purchased in accordance with <u>Section&#160;2</u> of this Agreement by the Maturity Date, this Agreement shall
        automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement (except as set forth below).</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Except as set forth in <u>Sections 11(a)</u> (in respect of a Suspension Event under <u>Sections 10(f)</u>, <u>10(g)</u> and 10(h)), <u>11(d)</u> and <u>11(e)</u>, any termination of this Agreement pursuant to
        this <u>Section 11</u> shall be effected by written notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination hereof.&#160; The representations and warranties and covenants
        of the Company and the Investor contained in <u>Sections 3</u>, <u>4</u>, <u>5</u>, and <u>6</u> hereof, the indemnification provisions set forth in <u>Section 9</u> hereof and the agreements and covenants set forth in <u>Sections</u><font style="font-weight: bold;"><u>&#160;</u></font><u>10</u>, <u>11</u> and <u>12</u> shall survive the execution and delivery of this Agreement and any termination of this Agreement. No termination of this Agreement shall (i) affect the Company&#8217;s or
        the Investor&#8217;s rights or obligations under (A) this Agreement with respect to pending Regular Purchases, Accelerated Purchases or Additional Accelerated Purchases and the Company and the Investor shall complete their respective obligations with
        respect to any pending Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases under this Agreement and (B) the Registration Rights Agreement, which shall survive any such termination, or (ii) be deemed to release the Company
        or the Investor from any liability for intentional misrepresentation or willful breach of any of the Transaction Documents.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">MISCELLANEOUS.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Governing Law; Jurisdiction; Jury Trial</u>.&#160; The corporate laws of the State of Delaware shall govern all issues concerning the relative rights of the Company and its stockholders.
        All other questions concerning the construction, validity, enforcement and interpretation of this Agreement, the Registration Rights Agreement and the other Transaction Documents shall be governed by the internal laws of the State of Illinois,
        without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois.&#160; Each
        party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Illinois, County of Cook, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection
        herewith or therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
        any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.&#160; Each party hereby irrevocably waives personal service of process and consents to process
        being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
        thereof.&#160; Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. <font style="font-weight: bold;">EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
          REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>.&#160; This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when
        counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a &#8220;.pdf&#8221; format data file, including any electronic signature complying with the U.S. federal
        ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original signature.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-32-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Headings</u>.&#160; The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Severability</u>.&#160; If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or
        enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Entire Agreement</u>.&#160; The Transaction Documents supersede all other prior oral or written agreements between the Investor, the Company, their affiliates and Persons acting on their
        behalf with respect to the subject matter thereof, and this Agreement, the other Transaction Documents and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and,
        except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters.&#160; The Company acknowledges and agrees that is has not relied on, in
        any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>.&#160; Any notices, consents or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been
        delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile or email (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one
        Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses for such communications shall be:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">If to the Company:</div>
      <div style="margin-left: 72pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z0ce4782d0f6b4ba89f995bf3fee394d5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>Eterna Therapeutics Inc.</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>1035 Cambridge Street, Suite 18A</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>Cambridge, MA 02141</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>Telephone:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>(212) 582-1199</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>E-mail:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>andrew.jackson@eternatx.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>Attention:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">&#160;</td>
              <td style="width: 85%; vertical-align: top;">
                <div>Chief Financial Officer</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">With a copy to (which shall not constitute notice or service of process):</div>
      <div style="margin-left: 72pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z5a778fc52afe41a1935dbfe94e94dcd8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>Greenberg Traurig, P.A.</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>333 S.E. 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Avenue, Suite 4400</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div>Miami, Florida 33131</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>Telephone:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>(305) 579-0589</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>Facsimile:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>(305) 961-5589</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>E-mail:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>altmand@gtlaw.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div>Attention:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div>Drew M. Altman, Esq.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-33-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If to the Investor:</div>
      <div style="margin-left: 72pt;">
        <table cellspacing="0" cellpadding="0" id="z3bf03cd1a15744b59cd41d34da290717" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">Lincoln Park Capital Fund, LLC</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">440 North Wells, Suite 410</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">Chicago, IL 60654</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Telephone:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">312-822-9300</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Facsimile:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">312-822-9301</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">E-mail:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Attention:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">Josh Scheinfeld/Jonathan Cope</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">With a copy to (which shall not constitute notice or service of process):</div>
      <div style="margin-left: 72pt;">
        <table cellspacing="0" cellpadding="0" id="z8f2302731afd4d679e2893575e171add" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">Dorsey &amp; Whitney LLP</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">51 West 52<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Street</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">New York, NY 10019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Telephone:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">(212) 415-9214</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Facsimile:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">(212) 953-7201</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">E-mail:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">marsico.anthony@dorsey.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Attention:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">Anthony J. Marsico, Esq.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"> <br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">If to the Transfer Agent:</div>
      <div style="margin-left: 72pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z9f8a6cb0d5b644b09b68be65e57ab290" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">Computershare Trust Company, N.A.</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">P.O. Box 43006</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify;">Providence, RI 02940-3006</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Telephone:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">(800) 736-3001</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; vertical-align: top;">
                <div style="text-align: justify;">Attention:</div>
              </td>
              <td style="width: 85%; vertical-align: top;">
                <div style="text-align: justify;">Issuance Department</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">or at such other address and/or facsimile number and/or email address and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party three (3) Business
        Days prior to the effectiveness of such change.&#160; Written confirmation of receipt (A) given by the recipient of such notice, consent or other communication, (B) mechanically or electronically generated by the sender&#8217;s facsimile machine or email
        account containing the time, date, and recipient facsimile number or email address, as applicable, and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable
        evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Successors and Assigns</u>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns.&#160; The Company shall
        not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor, including by merger or consolidation.&#160; The Investor may not assign its rights or obligations under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Third Party Beneficiaries</u>.&#160; This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns and, except as set forth in
        Section 9 with respect to those persons entitled to indemnity thereunder, is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Publicity</u>.&#160; The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the Investor and its counsel on the form and
        substance of, and shall give due consideration to all such comments from the Investor or its counsel on, any press release, SEC filing or any other public disclosure by or on behalf of the Company relating to the Investor, its purchases hereunder
        or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby, not less than 24 hours prior to the issuance, filing or public disclosure thereof. The Investor must be provided with a final version of any
        portion of such press release, SEC filing or other public disclosure relating to the Investor, its purchases hereunder or any aspect of the Securities, the Transaction Documents or the transactions contemplated thereby at least 24 hours prior to
        any release, issuance, filing or use by the Company thereof.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-34-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Further Assurances</u>.&#160; Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other
        agreements, certificates, instruments and documents, as the other party may reasonably request in order to consummate and make effective, as soon as reasonably possible, the Commencement, and to carry out the intent and accomplish the purposes of
        this Agreement and the consummation of the transactions contemplated hereby.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Financial Advisor, Placement Agent, Broker or Finder</u>.&#160; &#160; The Company represents and warrants to the Investor that it has not engaged any financial advisor, placement agent,
        broker or finder in connection with the transactions contemplated hereby.&#160; The Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions
        contemplated hereby.&#160; The Company shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder relating to or arising out of the transactions contemplated hereby.&#160; The Company
        shall pay, and hold the Investor harmless against, any liability, loss or expense (including, without limitation, reasonable attorneys&#8217; fees and out of pocket expenses) arising in connection with any such claim made by a third party for any such
        fees or commissions.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>No Strict Construction</u>.&#160; The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict
        construction will be applied against any party.<font style="color: rgb(0, 0, 0);"> In addition, each and every reference to share prices and shares of Common Stock in this Agreement shall be subject to adjustment as provided in this Agreement for
          reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Remedies, Other Obligations, Breaches and Injunctive Relief</u>.&#160; The Investor&#8217;s remedies provided in this Agreement, including, without limitation, the Investor&#8217;s remedies provided
        in Section 9, shall be cumulative and in addition to all other remedies available to the Investor under this Agreement, at law or in equity (including a decree of specific performance and/or other injunctive relief), no remedy of the Investor
        contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit the Investor&#8217;s right to pursue actual damages for any failure by the Company to comply with the terms of this
        Agreement.&#160; The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investor and that the remedy at law for any such breach may be inadequate.&#160; The Company therefore agrees that, in the event of
        any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being
        required.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Enforcement Costs</u>.&#160; If: (i) this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced by the Investor through any legal proceeding; (ii)
        an attorney is retained to represent the Investor in any bankruptcy, reorganization, receivership or other proceedings affecting creditors&#8217; rights and involving a claim under this Agreement; or (iii) an attorney is retained to represent the
        Investor in any other proceedings whatsoever in connection with this Agreement, then the Company shall pay to the Investor, as incurred by the Investor, all reasonable costs and expenses including attorneys&#8217; fees incurred in connection therewith,
        in addition to all other amounts due hereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Amendment and Waiver; Failure or Indulgence Not Waiver</u>.&#160; No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Business
        Day immediately preceding the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, (i) no provision of this Agreement may be amended other than by a written instrument signed by both parties
        hereto and (ii) no provision of this Agreement may be waived other than in a written instrument signed by the party against whom enforcement of such waiver is sought. No failure or delay in the exercise of any power, right or privilege hereunder
        shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privilege</div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic;">** Signature Page Follows **</div>
      <div style="text-align: center; font-style: italic;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-35-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold;">IN WITNESS WHEREOF,</font> the Investor and the Company have caused this Agreement to be duly executed as of the date first written above.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z50bdc6d12ff3468685f123f4d137f868" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;">
              <div style="text-align: justify; font-weight: bold;"><u>THE COMPANY:</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;">
              <div style="text-align: justify; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">By:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">/s/ Andrew Jackson</div>
            </td>
            <td style="width: 17%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" id="z20a5100068cd4f549d3a0cd6910fcba8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">Andrew Jackson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">:</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">Chief Financial Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;"><u>INVESTOR</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;"><u>:</u></div>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;">BY: LINCOLN PARK CAPITAL, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; font-weight: bold;">BY: ROCKLEDGE CAPITAL CORPORATION</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zaac0599895d141ed98a0f4db5e2c1321" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;">By:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;">/s/ Joshua Scheinfeld</div>
            </td>
            <td style="width: 17%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" id="z4abc16620ea1442088ffbf175735f88b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">Joshua Scheinfeld</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify;">President</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">-36-</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; font-weight: bold;"><u>EXHIBITS</u></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zf68a1bae876c4199a9373adf3a47c148" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="text-align: justify;">Exhibit A</div>
            </td>
            <td style="width: 85%; vertical-align: top;">
              <div style="text-align: justify;">Form of Officer&#8217;s Certificate</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="text-align: justify;">Exhibit B</div>
            </td>
            <td style="width: 85%; vertical-align: top;">
              <div style="text-align: justify;">Form of Secretary&#8217;s Certificate</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="text-align: justify;">Exhibit C</div>
            </td>
            <td style="width: 85%; vertical-align: top;">
              <div style="text-align: justify;">Form of Letter to Transfer Agent</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT A</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">FORM OF OFFICER&#8217;S CERTIFICATE</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 50.4pt;">This Officer&#8217;s Certificate (&#8220;<font style="font-weight: bold;">Certificate</font>&#8221;) is being delivered pursuant to <u>Section 8(e)</u> of that certain Purchase Agreement dated as of April 5,
        2023, (&#8220;<font style="font-weight: bold;">Purchase Agreement</font>&#8221;), by and between<font style="font-weight: bold;"> ETERNA THERAPEUTICS INC.</font>, a Delaware corporation (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), and <font style="font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC </font>(the &#8220;<font style="font-weight: bold;">Investor</font>&#8221;).&#160; Capitalized terms used herein and not otherwise defined shall have the respective meanings ascribed to them in the
        Purchase Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 50.4pt;">The undersigned, ___________, ______________ of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 27pt; margin-left: 54pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; I am the _____________ of the Company and make the statements contained in this Certificate;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 27pt; margin-left: 54pt;">2.&#160;&#160;&#160;&#160;&#160;&#160; The representations and warranties of the Company are true and correct in all material respects (except to the extent that any of such representations and warranties is
        already qualified as to materiality in Section 4 of the Purchase Agreement, in which case, such representations and warranties are true and correct without further qualification) as of the date when made and as of the Commencement Date as though
        made at that time (except for representations and warranties that speak as of a specific date, in which case such representations and warranties are true and correct as of such date);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 27pt; margin-left: 54pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the Transaction Documents to be
        performed, satisfied or complied with by the Company at or prior to the Commencement Date.</div>
      <div>
        <div style="text-align: justify; text-indent: 36pt; margin-right: 36pt; margin-left: 36pt;"> <br>
        </div>
        <div style="text-align: justify; text-indent: 27pt; margin-left: 54pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company has not taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of
          its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 18pt;">IN WITNESS WHEREOF, I have hereunder signed my name on this ___ day of ___________.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zb0c2e0a1505d48a1b521c6d00c897e8d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;"> <br>
            </td>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Name:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Title:</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The undersigned as Secretary of <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, a Delaware corporation, hereby certifies that ___________ is the duly elected, appointed,
        qualified and acting ________ of <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font> and that the signature appearing above is his genuine signature.</div>
      <br>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze0507bcd0f4e454daa794aa4d0238347">

          <tr>
            <td style="width: 49.99%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.99%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div>Secretary</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT B</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">FORM OF SECRETARY&#8217;S CERTIFICATE</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This Secretary&#8217;s Certificate (&#8220;Certificate&#8221;) is being delivered pursuant to <u>Section 8(k)</u> of that certain Purchase Agreement dated as of April 5, 2023 (&#8220;Purchase Agreement&#8221;), by and between
        <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, a Delaware corporation (the &#8220;Company&#8221;), and <font style="font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC</font> (the &#8220;Investor&#8221;), pursuant to which the Company may sell to the
        Investor up to Ten Million Dollars ($10,000,000) of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;Common Stock&#8221;).&#160; Capitalized terms used herein and not otherwise defined shall have the respective meanings ascribed to them in the
        Purchase Agreement.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">The undersigned, ____________, Secretary of the Company, hereby certifies, on behalf of the Company and not in his individual capacity, as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 36pt; margin-left: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; I am the Secretary of the Company and make the statements contained in this Secretary&#8217;s Certificate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 36pt; margin-left: 36pt;">2&#160;&#160;&#160;&#160;&#160;&#160; Attached hereto as <u>Exhibit A</u> and <u>Exhibit B</u> are true, correct and complete copies of the Company&#8217;s Amended and Restated Bylaws
        (&#8220;Bylaws&#8221;) and Restated Certificate of Incorporation (&#8220;Charter&#8221;), in each case, as amended through the date hereof, and no action has been taken by the Company, its directors, officers or stockholders, in contemplation of the filing of any further
        amendment relating to or affecting the Bylaws or Charter.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 36pt; margin-left: 36pt;">3. &#160; &#160;&#160;&#160;&#160; Attached hereto as <u>Exhibit C</u> are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company
        [at a meeting held on _____________, at which a quorum was present and acting throughout][by unanimous written consent].&#160; Such resolutions have not been amended, modified or rescinded and remain in full force and effect and such resolutions are the
        only resolutions adopted by the Company&#8217;s Board of Directors, or any committee thereof, or the stockholders of the Company relating to or affecting (i) the entering into and performance of the Purchase Agreement, the Registration Rights Agreement
        and the other Transaction Documents, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares, and (ii) and the performance of the Company of its obligations under each of the Transaction Documents as contemplated
        therein.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-right: 36pt; margin-left: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; As of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on <u>Exhibit D</u> hereto.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, I have hereunder signed my name on this ___ day of ____________, 202__.</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="za82769cd98c64288a7268ef9ef1bb201" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center;">&#160;[NAME]</div>
            </td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div style="text-align: center;">&#160;Secretary</div>
            </td>
            <td style="width: 20%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;">The undersigned as ______________ of <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, a Delaware corporation, hereby certifies that __________________ is the duly elected, appointed, qualified and
        acting Secretary of <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, and that the signature appearing above is his genuine signature.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="za0ddc1b213414e4f8f7750e31084ad97" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><br>
              </div>
            </td>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 35%; vertical-align: top;">
              <div style="text-align: center;">[NAME]</div>
            </td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 35%; vertical-align: top;">
              <div style="text-align: center;">[TITLE]</div>
            </td>
            <td style="width: 15%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>EXHIBIT C</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">FORM OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE COMMITMENT SHARES AT SIGNING OF THE PURCHASE AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: center;">[COMPANY LETTERHEAD]</div>
      <div><br>
      </div>
      <div>[________], 2023</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Computershare Transfer &amp; Trust Company, N.A.</div>
      <div style="text-align: justify;">P.O. Box 43006</div>
      <div style="text-align: justify;">Providence, RI 02940-3006</div>
      <div style="text-align: justify;">Attention: Issuance Department</div>
      <div><br>
      </div>
      <div>Re: Issuance of Common Stock to Lincoln Park Capital Fund, LLC</div>
      <div><br>
      </div>
      <div>Dear ________,</div>
      <div><br>
      </div>
      <div style="text-align: justify;">On behalf of <font style="font-weight: bold;">ETERNA THERAPEUTICS INC.</font>, a Delaware corporation (the &#8220;Company&#8221;), you are hereby instructed to issue <font style="font-weight: bold;"><u>as soon as possible</u>&#160;</font>a
        book-entry statement representing an aggregate of 73,659 shares of our common stock in the name of <font style="font-weight: bold;"><u>Lincoln Park Capital Fund, LLC</u></font>.&#160; The book-entry statement should be dated April 6, 2023.&#160; The
        book-entry statement should bear the following restrictive legend:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-right: 36pt; margin-left: 36pt; font-weight: bold;">THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
        SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
        SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER&#8217;S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>The book-entry statement should be sent <font style="font-weight: bold;"><u>as soon as possible via overnight mail</u></font> to the following address:</div>
      <div><br>
      </div>
      <div style="margin-left: 99pt;">Lincoln Park Capital Fund, LLC</div>
      <div style="margin-left: 99pt;">440 North Wells, Suite 410</div>
      <div style="margin-left: 99pt;">Chicago, IL 60654</div>
      <div style="margin-left: 99pt;">Attention: Josh Scheinfeld/Jonathan Cope</div>
      <div><br>
      </div>
      <div>Thank you very much for your help.&#160; Please call me at ______________ if you have any questions or need anything further.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">ETERNA THERAPEUTICS INC.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z5ac871e288a34cfdaaf80b42f4f3be20" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div>BY:</div>
            </td>
            <td colspan="1" style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 47%; vertical-align: top;">
              <div style="margin-left: 27pt;">[name]</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div><br>
              </div>
            </td>
            <td colspan="1" style="width: 47%; vertical-align: top;">
              <div style="margin-left: 27pt;">[title]</div>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>brhc10050812_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Exhibit 10.2<br>
      </div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">REGISTRATION RIGHTS AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">REGISTRATION RIGHTS AGREEMENT</font> (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;), dated as of April 5, 2023, by and between <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">ETERNA THERAPEUTICS INC., </font>a
        Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), and <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC,</font> an
        Illinois limited liability company (together with its permitted assigns, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Buyer</u></font>&#8221;).&#160; Capitalized terms used herein and not otherwise defined herein shall have the
        respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Agreement</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">WHEREAS:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">A.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Upon the terms and subject to the conditions of the
          Purchase Agreement, (i) the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Ten Million Dollars ($10,000,000) of the Company&#8217;s common stock, par value $0.005 per share (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;), pursuant to the Purchase Agreement (such shares, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Shares</u></font>&#8221;), and (ii) the Company has
          agreed to issue to the Investor such number of shares of Common Stock as consideration for its commitment to purchase shares of Common Stock under the Purchase Agreement at such time and otherwise in accordance with the terms set forth in Section
          5(e) of the Purchase Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Commitment Shares</u></font>&#8221;); and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">B.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">To induce the Buyer to enter into the Purchase
          Agreement, the Company has agreed to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221;), and applicable state securities laws.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">NOW, THEREFORE,</font> in consideration of the promises and the
        mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Buyer hereby, intending to be legally bound, agree as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>DEFINITIONS</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">As used in this Agreement, the following terms shall have the following meanings:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Investor</u></font>&#8221; means the Buyer, any transferee or assignee thereof to whom the Buyer assigns its rights under this Agreement in accordance with Section 9 and who agrees to become bound by the provisions of this Agreement,
          and any transferee or assignee thereof to whom a transferee or assignee assigns its rights under this Agreement in accordance with Section 9 and who agrees to become bound by the provisions of this Agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Person</u></font>&#8221; means any individual or entity including but not limited to any corporation, a limited liability company, an association, a partnership, an organization, a business, an individual, a governmental or political
          subdivision thereof or a governmental agency.</font></div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Register</u></font>,&#8221; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>registered</u></font>,&#8221; and &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>registration</u></font>&#8221; refer to a
            registration effected by preparing and filing one or more Registration Statements of the Company in compliance with the Securities Act and pursuant to Rule 415 under the Securities Act or any successor rule providing for offering securities on
            a continuous basis (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 415</u></font>&#8221;), and the declaration or ordering of effectiveness of such Registration Statement(s) by the United States Securities and Exchange
            Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC</u></font>&#8221;).</font></div>
      </div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registrable Securities</u></font>&#8221; means all of the Commitment Shares and all of the Purchase Shares, that may, from time to time, be issued or become issuable to the Investor under the Purchase Agreement (without regard to any
          limitation or restriction on purchases), and any and all shares of capital stock issued or issuable with respect to the Purchase Shares, the Commitment Shares<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>or




          the Purchase Agreement as a result of any stock split, stock dividend, recapitalization, exchange or similar event or otherwise, without regard to any limitation on purchases under the Purchase Agreement</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221; means one or more registration statements of the Company covering only the resale of the Registrable Securities, including, for the avoidance of doubt, any New Registration Statement (as
          defined below).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>REGISTRATION</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mandatory Registration.</u></font>&#160; The Company shall, within ten (10) Business Days after the date hereof, file with the SEC an initial Registration Statement on Form S-1 covering the maximum number of Registrable Securities,
          which shall include all of the Commitment Shares and such number of additional Registrable Securities as shall be permitted to be included thereon in accordance with applicable SEC rules, regulations and interpretations so as to permit the resale
          of such Registrable Securities by the Investor under Rule 415 under the Securities Act at then prevailing market prices (and not fixed prices), as mutually determined by both the Company and the Investor in consultation with their respective
          legal counsel, subject to the aggregate number of authorized shares of the Company&#8217;s Common Stock then available for issuance in the Certificate of Incorporation. The initial Registration Statement shall register only the Registrable Securities.
          The Investor and its counsel shall have a reasonable opportunity to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related prospectus prior to its filing with the SEC,
          and the Company shall give due consideration to all such comments. The Investor acknowledges that it will be identified in the initial Registration Statement (and in any New Registration Statement) as an underwriter within the meaning of Section
          2(a)(11) of the Securities Act, and the Investor shall furnish all information reasonably requested by the Company for inclusion therein. The Company shall use its commercially reasonable efforts to have the Registration Statement and any
          amendment declared effective by the SEC at the earliest possible date. The Company shall use reasonable best efforts to keep the Registration Statement effective pursuant to Rule 415 promulgated under the Securities Act and available for the
          resale by the Investor of all of the Registrable Securities covered thereby at all times until the earlier of (i) the date on which the Investor shall have resold all the Registrable Securities covered thereby and no Available Amount remains
          under the Purchase Agreement and (2) the six (6) month anniversary of the termination of the Purchase Agreement pursuant to Section 11 thereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Period</u></font>&#8221;).



          The Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary
          to make the statements therein, in light of the circumstances in which they were made, not misleading.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 424 Prospectus</u></font>.&#160; The Company shall, as required by applicable securities regulations, from time to time file with the SEC, pursuant to Rule 424 promulgated under the Securities Act, the prospectus and prospectus
          supplements, if any, to be used in connection with sales of the Registrable Securities under the Registration Statement.&#160; The Investor and its counsel shall have a reasonable opportunity to review and comment upon such prospectus prior to its
          filing with the SEC, and the Company shall give due consideration to all such comments.&#160; The Investor shall use its reasonable best efforts to comment upon such prospectus within one (1) Business Day from the date the Investor receives the
          substantially final pre-filing version of such prospectus.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Sufficient Number of Shares Registered</u></font>.&#160; In the event the number of shares available under the Registration Statement is insufficient to cover all of the Registrable Securities, the Company shall, to the extent
          necessary and permissible, amend the Registration Statement or file a new Registration Statement (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>New Registration Statement</u></font>&#8221;), so as to cover all of such Registrable
          Securities (subject to the limitations set forth in Section 2(a)) as soon as reasonably practicable, but in any event not later than ten (10) Business Days after the necessity therefor arises, subject to any limits that may be imposed by the SEC
          pursuant to Rule 415 under the Securities Act.&#160; The Company shall use its commercially reasonable efforts to cause such amendment and/or New Registration Statement to become effective as soon as reasonably practicable following the filing
          thereof.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Offering</u></font>.&#160; If the staff of the SEC (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Staff</u></font>&#8221;) or the SEC seeks to characterize any offering pursuant to a Registration Statement filed
          pursuant to this Agreement as constituting an offering of securities that does not permit such Registration Statement to become effective and be used for resales by the Investor under Rule 415 at then-prevailing market prices (and not fixed
          prices), or if after the filing of the initial Registration Statement with the SEC pursuant to Section 2(a), the Company is otherwise required by the Staff or the SEC to reduce the number of Registrable Securities included in such initial
          Registration Statement, then the Company shall reduce the number of Registrable Securities to be included in such initial Registration Statement (after consulting with the Investor and its legal counsel as to the specific Registrable Securities
          to be removed therefrom) until such time as the Staff and the SEC shall so permit such Registration Statement to become effective and be used as aforesaid.&#160; In the event of any reduction in Registrable Securities pursuant to this paragraph, the
          Company shall file one or more New Registration Statements in accordance with Section 2(c) until such time as all Registrable Securities have been included in Registration Statements that have been declared effective and the prospectus contained
          therein is available for use by the Investor.&#160; Notwithstanding any provision herein or in the Purchase Agreement to the contrary, the Company&#8217;s obligations to register Registrable Securities (and any related conditions to the Investor&#8217;s
          obligations) shall be qualified as necessary to comport with any requirement of the SEC or the Staff as addressed in this Section 2(d).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>RELATED OBLIGATIONS</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">With respect to the Registration Statement and whenever any Registrable Securities are to be registered pursuant to Section 2 including on any New
        Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have
        the following obligations:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall prepare and file with the SEC
          such amendments (including post-effective amendments) and supplements to any Registration Statement and the prospectus used in connection with such Registration Statement, which prospectus is to be filed pursuant to Rule 424 promulgated under the
          Securities Act, as may be necessary to keep the Registration Statement or any New Registration Statement effective at all times during the Registration Period, and, during such period, comply with the applicable provisions of the Securities Act
          with respect to the disposition of all Registrable Securities of the Company covered by the Registration Statement or any New Registration Statement until such time as all of such Registrable Securities shall have been disposed of in accordance
          with the intended methods of disposition by the seller or sellers thereof as set forth in such Registration Statement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall permit the Investor to review and
          comment upon the Registration Statement or any New Registration Statement and all amendments and supplements thereto at least two (2) Business Days prior to their filing with the SEC, and not file any such document in a form to which the Investor
          reasonably objects in writing.&#160; The Investor shall use its reasonable best efforts to comment upon the Registration Statement or any New Registration Statement and any amendments or supplements thereto within one (1) Business Day from the date
          the Investor receives the substantially final version thereof.&#160; The Company shall furnish to the Investor, without charge, any correspondence from the SEC or the staff of the SEC to the Company or its representatives relating to the Registration
          Statement or any New Registration Statement.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Upon request of the Investor, the Company shall
          furnish to the Investor, (i) promptly after the same is prepared and filed with the SEC, at least one copy of any Registration Statement and any amendment(s) thereto, including financial statements and schedules, all documents incorporated
          therein by reference and all exhibits, (ii) upon the effectiveness of any Registration Statement, a copy of the prospectus included in such Registration Statement and all amendments and supplements thereto (or such other number of copies as the
          Investor may reasonably request) and (iii) such other documents, including copies of any preliminary or final prospectus, as the Investor may reasonably request from time to time in order to facilitate the disposition of the Registrable
          Securities owned by the Investor. For the avoidance of doubt, any filing available to the Investor via the SEC&#8217;s live EDGAR system shall be deemed &#8220;furnished to the Investor&#8221; or &#8220;delivered&#8221; to the Investor hereunder.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall use commercially reasonable
          efforts to (i) register and qualify the Registrable Securities covered by any Registration Statement under such other securities or &#8220;blue sky&#8221; laws of such jurisdictions in the United States as the Investor reasonably requests, (ii) prepare and
          file in those jurisdictions, such amendments (including post-effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof during the Registration Period, (iii) take such
          other actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all other actions reasonably necessary or advisable to qualify the Registrable Securities for
          sale in such jurisdictions; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for
          this Section 3(d), (y) subject itself to taxation in any such jurisdiction, or (z) file a general consent to service of process in any such jurisdiction.&#160; The Company shall promptly notify the Investor who holds Registrable Securities of the
          receipt by the Company of any notification with respect to the suspension of the registration or qualification of any of the Registrable Securities for sale under the securities or &#8220;blue sky&#8221; laws of any jurisdiction in the United States or its
          receipt of written notice of the initiation or threatening of any proceeding for such purpose.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">As promptly as reasonably practicable after
          becoming aware of any event or fact, the result of which makes a material fact included in any Registration Statement, as then in effect, or any prospectus included therein untrue or results in the omission of a material fact required to be
          stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, the Company shall notify the Investor in writing of the
          happening of such event or existence of such facts and promptly prepare a supplement or amendment to such Registration Statement to correct such untrue statement or omission, and deliver a copy of such supplement or amendment to the Investor.&#160;
          The Company shall also promptly notify the Investor in writing (i) when a prospectus or any prospectus supplement or post-effective amendment has been filed, and when any Registration Statement or any post-effective amendment has become effective
          (notification of such effectiveness shall be delivered to the Investor by email or facsimile on the same day of such effectiveness or by overnight mail), (ii) of any request by the SEC for amendments or supplements to any Registration Statement
          or related prospectus or related information, and (iii) of the Company&#8217;s reasonable determination that a post-effective amendment to any Registration Statement would be appropriate.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall use its commercially reasonable
          efforts to prevent the issuance of any stop order or other suspension of effectiveness of any Registration Statement, or the suspension of the qualification of any Registrable Securities for sale in any jurisdiction and, if such an order or
          suspension is issued, to obtain the withdrawal of such order or suspension at the earliest possible moment and to notify the Investor of the issuance of such order and the resolution thereof or its receipt of actual notice of the initiation or
          threat of any proceeding for such purpose.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">g.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall (i) cause all the Registrable
          Securities to be listed on the Principal Market if the listing of such Registrable Securities is then permitted under the rules of the Principal Market, or (ii) secure designation and quotation of all the Registrable Securities on the Principal
          Market.&#160; The Company shall pay all fees and expenses in connection with satisfying its obligation under this Section.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">h.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #010101;">The </font>Company shall cooperate with the Investor to facilitate the timely issuance of the Registrable Securities to be offered pursuant to any Registration Statement, it being agreed that such Registrable
          Securities shall be issued as DWAC Shares and in such denominations or amounts as the Investor may reasonably request and registered in such names as the Investor may request.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall at all times provide a transfer
          agent and registrar with respect to its Common Stock.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">j.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #010101;">If reasonably requested in writing by the Investor, the Company shall:&#160; (i) as soon as practicable, incorporate in a prospectus supplement or post-effective amendment such information as the Investor reasonably
            requests be included therein relating to the sale and distribution of Registrable Securities, including, without limitation, information with respect to the number of Registrable Securities</font> being sold, the purchase price being paid
          therefor and any other terms of the offering of the Registrable Securities; (ii) make all required filings of such prospectus supplement or post-effective amendment as soon as practicable upon notification of the matters to be incorporated in
          such prospectus supplement or post-effective amendment; and (iii) supplement or make amendments to any Registration Statement or New Registration Statement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">k.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall use its commercially reasonable
          efforts to cause the Registrable Securities covered by any Registration Statement to be registered with or approved by such other governmental agencies or authorities as may be necessary to consummate the disposition of such Registrable
          Securities.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">l.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Within one (1) Business Day after any Registration
          Statement which includes the Registrable Securities is declared effective by the SEC, the Company shall deliver, and shall direct legal counsel for the Company to deliver, to the transfer agent for such Registrable Securities (with copies to the
          Investor) confirmation that such Registration Statement has been declared effective by the SEC in substantially the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font>.&#160; Thereafter, if
          requested by the Investor at any time, the Company shall direct its counsel to deliver to the Investor a written confirmation whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including,
          without limitation, the issuance of a stop order) and whether or not the Registration Statement is current and available to the Investor for sale of all of the Registrable Securities.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">m.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall take such other reasonable
          actions necessary to expedite and facilitate disposition by the Investor of Registrable Securities pursuant to any Registration Statement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>OBLIGATIONS OF THE INVESTOR</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company shall notify the Investor in writing of
          the information the Company reasonably requires from the Investor in connection with any Registration Statement hereunder.&#160; The Investor shall promptly furnish to the Company such information regarding itself, the Registrable Securities held by
          it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as
          the Company may reasonably request.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Investor agrees to cooperate with the Company
          as reasonably requested by the Company in connection with the preparation and filing of any Registration Statement hereunder.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Investor agrees that, upon receipt of any
          notice from the Company of the happening of any event or existence of facts of the kind described in Section 3(f) or the first sentence of 3(e), the Investor will immediately discontinue disposition of Registrable Securities pursuant to any
          Registration Statement(s) covering such Registrable Securities until the Investor&#8217;s receipt of the copies of the supplemented or amended prospectus contemplated by Section 3(f) or the first sentence of 3(e).&#160; Notwithstanding anything to the
          contrary, the Company shall direct its transfer agent to promptly deliver shares of Common Stock without any restrictive legend in accordance with the terms of the Purchase Agreement in connection with any sale of Registrable Securities with
          respect to which an Investor has entered into a contract for sale prior to the Investor&#8217;s receipt of a notice from the Company of the happening of any event of the kind described in Section 3(f) or the first sentence of Section 3(e) and for which
          the Investor has not yet settled.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>EXPENSES OF REGISTRATION</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">All reasonable expenses, other than sales or brokerage commissions, incurred in connection with registrations, filings or qualifications pursuant to
        Sections 2 and 3, including, without limitation, all registration, listing and qualifications fees, printers and accounting fees, and fees and disbursements of counsel for the Company, shall be paid by the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify;">
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>INDEMNIFICATION</u></font>.</font></div>
      </div>
      <font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
      </font>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">To the fullest extent permitted by law, the Company
          will, and hereby does, indemnify, hold harmless and defend the Investor, each Person, if any, who controls the Investor, the members, the directors, officers, partners, employees, agents, representatives of the Investor and each Person, if any,
          who controls the Investor within the meaning of Section 20 of the Securities Exchange Act of 1934, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exchange Act</u></font>&#8221;) (each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnified Person</u></font>&#8221;), against any losses, claims, damages, liabilities, judgments, fines, penalties, charges, costs, reasonable attorneys&#8217; fees, amounts paid in settlement or expenses, joint
          or several, (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Claims</u></font>&#8221;) incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from
          the foregoing by or before any court or governmental, administrative or other regulatory agency, body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnified Damages</u></font>&#8221;), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based
          upon: (i) any untrue statement or alleged untrue statement of a material fact in the Registration Statement, any New Registration Statement or any post-effective amendment thereto or in any filing made by the Company in connection with the
          qualification of the offering under the securities or other &#8220;blue sky&#8221; laws of any jurisdiction in which Registrable Securities are offered (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Blue Sky Filing</u></font>&#8221;), or the
          omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) any untrue statement or alleged untrue statement of a material fact contained in the final
          prospectus (as amended or supplemented, if the Company files any amendment thereof or supplement thereto with the SEC) or the omission or alleged omission to state therein any material fact necessary to make the statements made therein, in light
          of the circumstances under which the statements therein were made, not misleading, (iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any other law, including, without limitation, any state securities
          law, or any rule or regulation thereunder relating to the offer or sale of the Registrable Securities pursuant to the Registration Statement or any New Registration Statement&#160; or (iv) any material violation by the Company of this Agreement (the
          matters in the foregoing clauses (i) through (iv) being, collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Violations</u></font>&#8221;).&#160; The Company shall reimburse each Indemnified Person promptly as such expenses are
          incurred and are due and payable, for any reasonable and documented legal fees or other reasonable expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein,
          the indemnification agreement contained in this Section 6(a): (i) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information about the Investor
          furnished in writing to the Company by such Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement or any such amendment thereof or supplement thereto, if such
          prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e); (ii) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim
          purchased the Registrable Securities that are the subject thereof (or to the benefit of any Person controlling such Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised
          prospectus, as then amended or supplemented, if such revised prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e), and the Indemnified Person was promptly advised in writing not to use the incorrect
          prospectus prior to the use giving rise to a violation and such Indemnified Person, notwithstanding such advice, used it; (iii) shall not be available to the extent such Claim is based on a failure of the Investor to deliver or to cause to be
          delivered the prospectus made available by the Company, if such prospectus was timely made available by the Company pursuant to Section 3(c) or Section 3(e); and (iv) shall not apply to amounts paid in settlement of any Claim if such settlement
          is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld.&#160; Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person
          and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section 9.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">In connection with the Registration Statement or
          any New Registration Statement, the Investor agrees to indemnify, hold harmless and defend, to the same extent and in the same manner as is set forth in Section 6(a), the Company, each of its directors, each of its officers who signs the
          Registration Statement or any New Registration Statement, each Person, if any, who controls the Company within the meaning of Section 20 of the Exchange Act (collectively and together with an Indemnified Person, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnified Party</u></font>&#8221;), against any Claim or Indemnified Damages to which any of them may become subject, under the Securities Act, the Exchange Act or otherwise, insofar as such Claim or Indemnified
          Damages arise out of or are based upon any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with written information about the Investor set forth on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> attached hereto and furnished to the Company by the Investor expressly for use in connection with such Registration Statement; and, subject to Section 6(d), the
          Investor will reimburse any legal or other expenses reasonably incurred (and documented) by them in connection with investigating or defending any such Claim; provided, however, that the indemnity agreement contained in this Section 6(b) and the
          agreement with respect to contribution contained in Section 7 shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Investor, which consent shall not be unreasonably
          withheld; provided, further, however, that the Investor shall be liable under this Section 6(b) for only that amount of a Claim or Indemnified Damages as does not exceed the net proceeds to the Investor as a result of the sale of Registrable
          Securities pursuant to such Registration Statement.&#160; Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities
          by the Investor pursuant to Section 9.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Promptly after receipt by an Indemnified Person or
          Indemnified Party under this Section 6 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect
          thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the
          indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party,
          as the case may be; provided, however, that an Indemnified Person or Indemnified Party shall have the right to retain its own counsel with the reasonable and documented fees and expenses to be paid by the indemnifying party, if, in the reasonable
          opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such
          Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding.&#160; The Indemnified Party or Indemnified Person shall cooperate fully with the indemnifying party in connection with any negotiation or
          defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim.&#160; The indemnifying
          party shall keep the Indemnified Party or Indemnified Person fully apprised at all times as to the status of the defense or any settlement negotiations with respect thereto.&#160; No indemnifying party shall be liable for any settlement of any action,
          claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent.&#160; No indemnifying party shall, without the consent of the Indemnified Party
          or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party or Indemnified
          Person of a release from all liability in respect to such claim or litigation.&#160; Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with
          respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.&#160; The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action
          shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The indemnification required by this Section 6
          shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The indemnity agreements contained herein shall be
          in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>CONTRIBUTION</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum
        contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within
        the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall
        be limited in amount to the net amount of proceeds received by such seller from the sale of such Registrable Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>REPORTS AND DISCLOSURE UNDER THE SECURITIES ACT</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">With a view to making available to the Investor the benefits of Rule 144 promulgated under the Securities Act or any other similar rule or
        regulation of the SEC that may at any time permit the Investor to sell securities of the Company to the public without registration (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 144</u></font>&#8221;), the Company agrees, at
        the Company&#8217;s sole expense, for as long as the Investor owns Registrable Securities, to use commercially reasonable efforts to:</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">make and keep public information available, as
          those terms are understood and defined in Rule 144;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">file with the SEC all reports and other documents
          required of the Company under the Securities Act and the Exchange Act so long as the Company remains subject to such requirements and the filing of such reports and other documents is required for the applicable provisions of Rule 144;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">furnish to the Investor promptly upon request (i) a
          written statement by the Company that it has complied with the reporting and or disclosure provisions of Rule 144(c), the Securities Act and the Exchange Act, (ii) a copy of the most recent annual or quarterly report of the Company and such other
          reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested to permit the Investor to sell such securities pursuant to Rule 144 without registration; and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: #010101; font-family: 'Times New Roman'; font-size: 10pt;">take such additional action as is
          reasonably requested by the Investor to enable the Investor to sell the Registrable Securities pursuant to Rule 144, including, without limitation, delivering all such legal opinions, consents, certificates, resolutions and instructions to the
          Transfer Agent as may be requested from time to time by the Investor and otherwise reasonably cooperate with Investor and the Investor&#8217;s broker to effect such sale of securities pursuant to Rule 144; provided, however, the Investor shall provide
          such documents as may be reasonably required by the Transfer Agent in connection therewith, including any written representations or certifications of the Investor or its broker (which shall not include any opinion of the Investor&#8217;s counsel) that
          may be reasonably required by the Transfer Agent in connection therewith.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company agrees that damages may be an inadequate remedy for any breach of the terms and provisions of this Section 8 and that Investor shall,
        whether or not it is pursuing any remedies at law, be entitled to seek equitable relief in the form of a preliminary or permanent injunctions, without having to post any bond or other security, upon any breach or threatened breach of any such terms
        or provisions.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>ASSIGNMENT OF REGISTRATION RIGHTS</u></font>.</div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; margin-left: 36pt;"> <br>
        </div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: #010101;">The Company shall not assign this Agreement or any rights or
          obligations hereunder without the prior written consent of the Investor; provided, however, that any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company remains the surviving
          entity immediately after such transaction shall not be deemed an assignment. The Investor may not assign its rights under this Agreement without the prior written consent of the Company, other than to an affiliate of the Investor controlled by
          Jonathan Cope or Joshua Scheinfeld, in which case the assignee must agree in writing to be bound by the terms and conditions of this Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman';">.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>AMENDMENT OF REGISTRATION RIGHTS</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">No provision of this Agreement may be amended or waived by the parties from and after the date that is one (1) Business Day immediately preceding
        the initial filing of the Registration Statement with the SEC. Subject to the immediately preceding sentence, no provision of this Agreement may be (i) amended other than by a written instrument signed by both parties hereto or (ii) waived other
        than in a written instrument signed by the party against whom enforcement of such waiver is sought. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in exercising such right or remedy,
        shall not operate as a waiver thereof.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>MISCELLANEOUS</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">A Person is deemed to be a holder of Registrable
          Securities whenever such Person owns or is deemed to own of record such Registrable Securities.&#160; If the Company receives conflicting instructions, notices or elections from two or more Persons with respect to the same Registrable Securities, the
          Company shall act upon the basis of instructions, notice or election received from the registered owner of such Registrable Securities as set forth on the books and records of the Transfer Agent.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Any notices, consents, waivers or other
          communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered:&#160; (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile or email
          (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case properly
          addressed to the party to receive the same.&#160; The addresses, email addresses and facsimile numbers for such communications shall be:</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If to the Company:</div>
      <div style="margin-left: 63pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z4e0b8f7981e24e5b8e71724b07e5f1b3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Eterna Therapeutics Inc.</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">1035 Cambridge Street, Suite 18A</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cambridge, MA 02141</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Telephone:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(212) 582-1199</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">E-mail:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">andrew.jackson@eternatx.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attention:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Andrew Jackson</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;"><br>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Chief Financial Officer</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">With a copy to (which shall not constitute notice or service of process):</div>
      <div style="margin-left: 63pt;">
        <table cellspacing="0" cellpadding="0" id="z0a3a2ce0abf74d6885f649f7e6d4a3b9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Greenberg Traurig, P.A.</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">333 S.E. 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Avenue, Suite 4400</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Miami, Florida 33131</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Telephone:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(305) 579-0589</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(305) 961-5589</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E-mail:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">altmand@gtlaw.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Attention:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Drew M. Altman, Esq.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">If to the Investor:</div>
      <div style="margin-left: 63pt;">
        <table cellspacing="0" cellpadding="0" id="z1261438029d742f39f502f179ca1a201" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Lincoln Park Capital Fund, LLC</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">440 North Wells, Suite 410</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Chicago, IL 60654</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Telephone:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">312-822-9300</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">312-822-9301</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">E-mail:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">jscheinfeld@lpcfunds.com/jcope@lpcfunds.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attention:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Josh Scheinfeld/Jonathan Cope</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">With a copy to (which shall not constitute notice or service of process):</div>
      <div><br>
      </div>
      <div style="margin-left: 63pt;">
        <table cellspacing="0" cellpadding="0" id="zb45375d4e2184bd7aeec9ee0446a6a88" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Dorsey &amp; Whitney LLP</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">51 West 52<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Street</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;" rowspan="1" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">New York, NY 10019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Telephone:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(212) 415-9214</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Facsimile:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">(212) 953-7201</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">E-mail:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">marsico.anthony@dorsey.com</div>
              </td>
            </tr>
            <tr>
              <td style="width: 12%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attention:</div>
              </td>
              <td style="width: 88%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Anthony J. Marsico, Esq.</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">or at such other address and/or facsimile number and/or to the attention of such other Person as the recipient party has specified by written notice given to each
        other party three (3) Business Days prior to the effectiveness of such change.&#160; Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically generated by the
        sender&#8217;s facsimile machine or email account containing the time, date, recipient facsimile number or email address, as applicable, and an image of the first page of such transmission or (C) provided by a nationally recognized overnight delivery
        service, shall be rebuttable evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The corporate laws of the State of Delaware shall
          govern all issues concerning the relative rights of the Company and its stockholders.&#160; All other questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State
          of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of
          Illinois.&#160; Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Illinois, County of Cook, for the adjudication of any dispute hereunder or in connection herewith or with any
          transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
          action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.&#160; Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
          action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.&#160; Nothing contained
          herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.&#160; If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect
          the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other jurisdiction.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
            CONTEMPLATED HEREBY.</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">This Agreement and the Purchase Agreement
          constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof.&#160; There are no restrictions, promises, warranties or undertakings among the parties hereto, other than those set forth or referred to
          herein and therein.&#160; This Agreement and the Purchase Agreement supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof and thereof.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">This Agreement is intended for the benefit of the
          parties hereto and, subject to the requirements of Section 9, their successors and permitted assigns and, except as set forth in Section 6 with respect to those Persons entitled to indemnity thereunder, is not for the benefit of, nor may any
          provision hereof be enforced by, any other Person.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The headings in this Agreement are for convenience
          of reference only and shall not limit or otherwise affect the meaning hereof.</font></div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">g.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">This Agreement may be executed in two or more
          identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature
          delivered by e-mail in a &#8220;.pdf&#8221; format data file, including any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com, www.echosign.adobe.com, etc., shall be considered due execution and shall be binding
          upon the signatory thereto with the same force and effect as if the signature were an original signature.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">h.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Each party shall do and perform, or cause to be
          done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the
          purposes of this Agreement and the consummation of the transactions contemplated hereby.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The language used in this Agreement will be deemed
          to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against any party.&#160; The term &#8220;or&#8221; shall not be exclusive.</font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">* * * * * *</div>
      <div style="text-align: justify; text-indent: 191.5pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IN WITNESS WHEREOF,</font> the parties have caused this
        Registration Rights Agreement to be duly executed as of day and year first above written.</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="ze9f0f39a89194c789e29c9b219c5ef42" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u><font style="font-size: 10pt; font-family: 'Times New Roman';">THE COMPANY</font>:</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 49.94%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top; width: 50%;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ETERNA THERAPEUTICS INC.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Andrew Jackson</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;" rowspan="1">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7185c9812d6d430092cb968a8a9f0443">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Andrew Jackson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfbf83b5789ec4583931ca241926a3e4a">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>BUYER:</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LINCOLN PARK CAPITAL FUND, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BY:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LINCOLN PARK CAPITAL, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BY:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ROCKLEDGE CAPITAL CORPORATION</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1dff7e07e4f04ce796fa6b69fc4d66e1">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">/s/ Joshua Scheinfeld</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
            <td style="vertical-align: top; width: 45%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Joshua Scheinfeld</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
            </td>
            <td style="vertical-align: top; width: 45%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">President</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT A</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>TO REGISTRATION RIGHTS AGREEMENT</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">FORM OF NOTICE OF EFFECTIVENESS</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OF REGISTRATION STATEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">[Date]</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Computershare Transfer &amp; Trust Company, N.A.</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">P.O. Box 43006</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Providence, RI 02940-3006</div>
      <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Telephone:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">(800) 736-3001</font></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Attention: Issuance Department</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Re: Eterna Therapeutics Inc.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Ladies and Gentlemen:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 40.5pt; font-family: 'Times New Roman'; font-size: 10pt;">We are counsel to Eterna Therapeutics Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;),




        and have represented the Company in connection with that certain Purchase Agreement, dated as of April 5, 2023 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Agreement</u></font>&#8221;), entered into by and between the
        Company and Lincoln Park Capital Fund, LLC (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Buyer</u></font>&#8221;), pursuant to which the Company has issued to the Buyer an aggregate of 73,659 shares of the Company&#8217;s common
        stock, par value $0.005 per share (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221;), as payment of a commitment fee for its commitment to purchase shares of Common Stock under the Purchase Agreement,
        and may in the future issue and sell to the Buyer up to Ten Million Dollars ($10,000,000) of Common Stock from time to time at the direction of the Company, upon the terms and subject to the conditions set forth in the Purchase Agreement.&#160; In
        connection with the transactions contemplated by the<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Purchase Agreement, the Company has registered with the U.S. Securities and Exchange Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC</u></font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221;), for resale by the Buyer
        an aggregate of [____________] shares of Common Stock, consisting of:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zfede65aa25604a5bb4777458ca8f97a9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">73,659 shares of Common Stock that have been issued to the Buyer upon execution of the Purchase Agreement as payment of a commitment fee (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Commitment Shares</u></font>&#8221;); and</div>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zfda204a745e84fbf9c7593f61ba211ca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">[____________] shares of Common Stock to be issued to the Buyer upon purchase by the Buyer from the Company at the Company&#8217;s direction from time to time in accordance with the
                terms of the Purchase Agreement (the<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Shares</u></font>&#8221;).</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Purchase Agreement, the Company also has entered into a Registration Rights Agreement, dated as of April 5, 2023, with the Buyer
        (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Rights Agreement</u></font>&#8221;), pursuant to which the Company has agreed, among other things, to register the under the Securities Act the Purchase Shares and the
        Commitment Shares for resale by the Buyer.&#160; In connection with the Company&#8217;s obligations under the Purchase Agreement and the Registration Rights Agreement, on [_________], 2023, the Company filed a Registration Statement on Form S-1 (File No.
        333-[_________]) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221;) with the SEC for the purpose of registering under the Securities Act the resale of the Purchase Shares and the Commitment
        Shares by the Buyer.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the foregoing, we advise you that the SEC entered an order declaring the Registration Statement effective under the Securities
        Act at [_____] [A.M./P.M.] on [__________], 2023, and, based solely on our review of the SEC&#8217;s website (located at http://www.sec.gov/litigation/stoporders.shtml), we confirm that, as of the date hereof no stop order suspending the effectiveness of
        the Registration Statement has been issued under the Securities Act.&#160; Therefore, you may issue the Purchase Shares and the Commitment Shares in accordance with instructions from the Company, from time to time, without any restrictive legend or stop
        transfer orders maintained against<font style="font-size: 10pt; font-family: 'Times New Roman'; color: #010101;"> them</font>.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zdbaf5cb9d13a4a00a14e29d1682212ae" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="vertical-align: top; width: 50%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Very truly yours,</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="vertical-align: top; width: 50%;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">[Company Counsel]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 24%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 23%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z2d7c25bede8a443e832b97c5be0aad2e">

          <tr>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">cc:</div>
            </td>
            <td style="width: 45%; vertical-align: top;" colspan="1">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Lincoln Park Capital Fund, LLC</div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><br>
              </div>
            </td>
            <td style="width: 46%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT B</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>TO REGISTRATION RIGHTS AGREEMENT</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Information About The Investor Furnished To The Company By The Investor</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Expressly For Use In Connection With The Registration Statement</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Information With Respect to Lincoln Park Capital</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of the date of the Purchase Agreement, Lincoln Park Capital Fund, LLC, beneficially owned 73,659 shares of our common stock.&#160; Josh Scheinfeld and Jonathan Cope, the
        Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared
        voting and investment power over the shares being offered under the prospectus filed with the SEC in connection with the transactions contemplated under the Purchase Agreement. Neither Lincoln Park Capital, LLC nor Lincoln Park Capital Fund, LLC is
        a registered broker-dealer or an affiliate of a registered broker-dealer.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>erna-20230405.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<xs:schema targetNamespace="http://eternatx.com/20230405" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:erna="http://eternatx.com/20230405" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20230405_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="erna-20230405_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://eternatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>erna-20230405_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>erna-20230405_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://eternatx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="erna-20230405.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://eternatx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140036319822496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  05,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eterna Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1035 Cambridge Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 18A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.005 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ERNA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>brhc10050812_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="erna-20230405.xsd" xlink:type="simple"/>
    <context id="c20230405to20230405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2023-04-05</startDate>
            <endDate>2023-04-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20230405to20230405"
      id="Fact_845a1b5c582048cfaf54e45d285a62c2">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20230405to20230405"
      id="Fact_9c7814419fd64747a86a6140dd4930fd">0000748592</dei:EntityCentralIndexKey>
    <dei:SecurityExchangeName
      contextRef="c20230405to20230405"
      id="Fact_ed129a2447cf4c71853a413e4d87b1a8">NASDAQ</dei:SecurityExchangeName>
    <dei:DocumentType
      contextRef="c20230405to20230405"
      id="Fact_dc49a7fe870e439aa89f5e6043cf9080">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20230405to20230405"
      id="Fact_5be4150dfe6b4b399f8b26deb6eb8347">2023-04-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20230405to20230405"
      id="Fact_595da8fc1f45425a8e04d042aeb6bc36">Eterna Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230405to20230405"
      id="Fact_5b122887297b44ef99e96ce1e0eb7107">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20230405to20230405"
      id="Fact_487d0a3cb3ec48baa5cde6f7d4eec1a6">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230405to20230405"
      id="Fact_5418c62b6e3147f791eab05719e427ef">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230405to20230405"
      id="Fact_834d2d330f564880aed1413ad2d0df1b">1035 Cambridge Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20230405to20230405"
      id="Fact_68c811f91eb346fe8cbc74c70de0b4fb">Suite 18A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20230405to20230405"
      id="Fact_0e32e15a74b549fd8d77ed73d77055a0">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230405to20230405"
      id="Fact_46f679009b97445c9bd947dc76ea28a8">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230405to20230405"
      id="Fact_10b2fd630e714af6850d0aed953cd38d">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230405to20230405"
      id="Fact_bb166c6003164e25b01f2ca4a43a3c59">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230405to20230405"
      id="Fact_a2f8d9b1af68438a84266c356939c664">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20230405to20230405"
      id="Fact_1b19edaaf3864c908445437d28a12821">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20230405to20230405"
      id="Fact_cec4dfc13efa47dab49838b2214c8e99">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20230405to20230405"
      id="Fact_9cd6242a89364e13ad94fc13472f4790">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20230405to20230405"
      id="Fact_385842461e27493a8c52f5d1f1409675">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20230405to20230405"
      id="Fact_f4805cc393924d0581d9b688175739f2">Common Stock, $0.005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230405to20230405"
      id="Fact_1f2b3a467d1f4955a84d07043039e00e">ERNA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230405to20230405"
      id="Fact_ca77247a8a0544d4ae8e7e6c8526cf9b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MY37HZOTN?3^P*BMVQ@ME89]='*X%!S8W ;Y?*F7?!VZS7?Y6,OH74$L#!!0
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( ,@[BU8'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ R#N+5DA Y-WM    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " #(.XM6'#AEZC\!   \ @  #P
M    @ %G$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ R#N+5B0>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ R#N+5F60>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10050812_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://eternatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName -  brhc10050812_8k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="brhc10050812_8k.htm">brhc10050812_8k.htm</File>
    <File>brhc10050812_ex10-1.htm</File>
    <File>brhc10050812_ex10-2.htm</File>
    <File>erna-20230405.xsd</File>
    <File>erna-20230405_lab.xml</File>
    <File>erna-20230405_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10050812_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10050812_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "erna-20230405_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "erna-20230405_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "erna-20230405.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "erna",
   "nsuri": "http://eternatx.com/20230405",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050812_8k.htm",
      "contextRef": "c20230405to20230405",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://eternatx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050812_8k.htm",
      "contextRef": "c20230405to20230405",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://eternatx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001140361-23-017671-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-017671-xbrl.zip
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M99H??"?) M)$HJ#(:1BG:28?50H.7 6%G4+$NI6)WR5?0BJD#ASCM?(1M?=
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M44I".=P$8!0'HSLCF:"D7\XPA*[>VZ/,/=R,(7.&V5$/!:A\[V25_@D7F!W
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MUNQ5H6[YHIBF&8PBZ$B>_'A=2>O%!NYHTG62N\0/-Q[C7AMZL^;%T[\C0?Z
MVS0Y+E;D,Q['0Q\8B#F%'E3Q!&^\?A*^=O;TJ+0_YDSN'.!10,%^"15U_7YO
M4%[3%0D]5UX6W"L"&]Y7\$S<^7FY?P^J+?MA,T8//;J]?(\=)D$&C?X.+CCO
M2M7<Z_44SZ4RMWT;QD-UU#OACSV31]-(A*Q9#?J,FQ2[<JY/-IWR[QU>G-%[
MN?6Y&9<"4>\(,CL/H&\?C'^GX^C?['EIL#S #]-B%L.'_P=02P,$%     @
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M >3@LXSK]0@$Y=C< XHP#($PZ$0\/AC!37T0*F&(YNSB$A[L[HNA%;:\5IP
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MGZ=;E'#G( E'FFQD?+&7[A7LC2L*W$E47%+.!LX!8ESIJ&*X3)D$JCK>G43
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M7KKN_N 6MT";4"[N[89M9P/L);&C[<.]4"X=TP>8<437E@C$;9@5(Q2RWQU
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M2S4J_XZ1-6#D57<VTCG/QO[LA:9$WS!,^<O-UI66WPFVW%3TJ$2DH7TB@-,
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M(UW#:&1J3GWJ9 .*B12YXZ?,)J%\E-5-&LRW>?/<-_A1R+*Z(\IB&U)0;",
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MEGU3F%ZX)U+((,A>O+O.=27)A0$-]]+A*MXUN+"H#*];T6V!M'U%KX@%]J'
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MIZ4"M 8;X[E@IW"MW."BPQ-&\D PM\=J75<E/E[,XST#%Q(<A11BXS;#STY
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MY[!@61::#U(GN&Y+29S;Q:.XHEU>=ZP_=,'MNPG,E"RS@MHRKAT*EBL[HM3
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M64AZM]YD)'AT'?T2%I?M)^(&^4Q'='XY$]/FY-%DV>DJ6#S9_%H0CL(IG1+
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MYRO;#8=OWWSC]X!Z=8:B)SR0U%[#DQTV&^!S+[%UE)D[]<9-+W_<Q,YJH,4
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M$3,7 +=RR(V1'(2 J%0F!R(AWGW["B8R+1ZN#G0]VP! X@ZUV"P%//D0<'@
MYCN+[KV+F=^J*YNX@3F/;VIV,#5LJY]R*G:<A@*Q22&'$/I3/CO@PA-_^GF^
MG"V&=]ZY?_OLFJ&C5$+GGN^%E#Z._+[$X^446]8(]P0-1UWR;>*E"/B%=V1'
MD)RP<12.C-@C@GD!/#IS4U$#K>^><WNEM>)HNC!Y,.\4L*?463JE:+9VD="4
MG:= =T1EB5H+:HDO.!$;?=GG=(GO*54.=622-".'(0;N,516<:0KN=1>XU^J
M!RVGVAV=^7=X;1 .",D3C4' B./>BF!YG^;'[R%:6"N_1 MWW=3OZ\K.PJ)(
MG.7$[F[,\T)%L3@;745B<B?(QY=5!JE$B*L5I*KAO9^D=[V3;Q+,D/?0 TB8
M2'TJ,*QQ]/LR"G(+2-@@-!3WN4C23]KE'XV<>*<CY@0=034/UY&.FVE;%J3B
MPB6"4S&/ISJ+Y8 B_J0$\=PZYE,O7H!,:L%!3'>*\OO89L*&ZCTW!8CF4OI:
MD=XOZ+BL*L,5V5(X9FG3N**B452.(!X,-B4YU%FI.ZJE0#?U$Z[.D!T]:^$$
MN6-&K6GA1=)TDS-WCPS6BDG%DEBG%-445<V)Z(UZ=XB=)[=R@J662J?'WC@&
M<RY9UZ-(-7V)MG,QI VG]NC^W9$RW%5DX6_60)DWN&S&$D,W3,F::6E65UUA
MK\?<NF8$L%+@.&KT%>DZKKKR81?$/1-;E<=(;/7;5^\[7:P4WUE&J^\"B7(E
MB8VE&B9!RDL]OSQ49W1_O\*MPRSR+_0)N[TC9YQ?"G8F:AG/KSF&'HG41+.,
M-50EQYX@G0YV!N.XI@[]K8T*-P)[?Q]CC[.5LIMID*M:_!0MM#TZ$FG\5LK*
ML29^-76%^NN:CA101O3!3>K@RH6_!1!Z:+<BZ\ L88>\3!>!HP1UU5VJ-$PC
M3@)_'P6[ 2DQ5*M_/X.#J<OTC)KF4FE:*SM05=LE #J2,,]8P_+E+1\;$7T6
M@H,X( 5BRW&\QC(?NB:#AGW0&*$K&X;3)O5J(MI4NLT:6"EL9W/8<>TY]9^U
MEM=+P'BNE+QJN5HK83F?AI3DX*M G<?0EX7FM O%7>;>D5S)Q_0'8+?FXK"X
M[)\0H(<PF]N-E:XY!G=$,]2M4>49PFYAFZ:(WL<B0U&P !#NOZ 0.MIN5,2\
MSAT3G"L:C@G*SK[]0$?[U#!2LV4*M=%D2C6(V^2HV?L<<G1:-&(QAA4JX">3
MURIY-_&MVDIS00MIB@RM^DD)()_NLE+15(:RSED8X[*R &.$.,[(>1&3U)D6
M-"7@269&DNH\B%)[:4TGABO#5?<R*B4/<9<Z^+3XW!TEFEJR6\L[VAN2Q-2H
MQ,?'[.5D4@M#/*@XWSO%>ED-C+L+/;U5IK"UC==84(0;STR%>=%:3"63V*B8
MQB*[I$DQE3K@$V[/=QG-\=E]76 @*RX\MMB=MJ^TPX!./?<(%0XT_PB_5<LF
MB6$'ZH5N-K1UZ^BC7&*4%;M<HASGO*-V6IRF!(G1M8C&D!6WLBA M8H6IE;7
M(B>G]/0N5N>6>/9;6%^2 S13")  E9,)0TBF \8LQ=,(H&1;1@&VJ-K>3VR!
M 6A^Z$66RR1CF<6I@Q3KMYQUDV:ZW<U*>XFYY\;<*R\Q]UVGJCNCTKHCH;1B
M1SH10+V%<T. ]KBF)U?I'!^EMPTKPO= Z ';4)]Y6?4C+*75>BAUKS4:XQM7
M%"L#H>V<)Z6<%V65LK>VYS8@Y?CZ]#K.KU>X]>C3[],7%77Z./Y^Q9IPHK33
MI#X<@14W.SG6M3"MS4E-)ZUN2^,Y7]? 92(ILF#-R7)S:A5=#_)V2M@3B9VO
M*&6,KO@))Z&TNZO?D:$?A0&RAO:"S&GFCW *Y>1[9 Y9QV27\U8S<U8W_VKH
M^< 9.A0>/!=?IQKP!&][P>KRFC(,H$>7(;_@URI<HP@:NP'*+(E30,SBDK2K
ML^*LP*I8+\ER_B5BFWH53(:S+#6JP\K%>P#(.*N7-PT!G7RJP!%3:C$SYJYE
MDT'WX-1&G >LL=?:S[.V96A"P[^FX_I)?D0_V2"6;XV^PO5)KVYP4=5WT=R3
M& SB56#$,@MBAHX:>-OAPU#6CC]7?<,O]T[VLV&3=+#*I:+12\P4L8I%43)Q
M+:>=9!Y"+9233'5:GAU1,M2&/*BP^W8*Z41ZR5Q8!MU;[D835G7A;X._\PAI
MF>ICI&7>=WJG[?/S5K=]\6&'O4;;I4&4UGJ+L%*PTJ$8S/M%%$O@7U J&/EC
M!-T5IXL&7P\9S[ (6)V6*F%788X!2TPQ5SCDYV($##$_OH1&Z62/(4@G2!"=
M U%O"+F+!3%, ;(6H\_(!T AEN9P*'E?E"C53KTK.4 1A)NB=M$,<&[R=6MI
M_2XU2HF&E(\[8:P*$HWUWW$ 4\9VS<BU,QY'TSB2"#;:I+R.O@CZ(M9BPYN8
M22H@!TWG-_>OTD?FR$6PC:6RR_<T1DW1LUU4$5E=DW C!F5W"!=$).YE'8I^
M.[B1<PN!F)'_>+T*V[ZDBR7K6..)&BJ/.V[JM_5]?^@^?:<LB$=ED549CDV#
MLR81F6)I]@<S'VJI+CG >1K'GTO&2/.#WY:!>'EXX2!*9DMF/*,3P6G26K5N
M4 $+L"$K 0,ZI*/:!#W+J4VR*\0M"X!+(-^X3!(1'D'(JZQ<;WW C6(L7%CZ
MY,91[W8X7]C&>,!IM%Z237Z6! P(+AOJ'X*[S# 11D2_+@EQ:M8D9(DA]54S
MQL%U[NTH&@$\3D,HZ-(M)1=E/48<Z%Q.2)P<@5+?+&W7_>H;1Q/*H\KU6KQ,
M29SFQ3T@]^&=B[=-#*^;J2?EST6J@QAAB!9(XA*L&.@ LKJ4N/$=%'E,6]E0
M/0O #X(YC&6D>R#) <+Q1(MB\X97B)@4?C]MKRGM' 'F)Y&O4#^B9K8I$@8]
MV[%BI1/4C2&]>"U<%EK2>7VVV *G97;+:)HF+8,B-8^.=.>_VH-SPDY9L%L(
M$"GK38-VZ_2==]FZZG_RWK6OVB>?O,[55?O7B]/6R?DG[V.K\VN[Y[6ZG[RK
MSMMW?:_3]]ZWU*6M7]O*]NR>>:VW5VUU1?>B[_4O9&SJJOV/#^U>7UWE_?+A
MZI/7O^JTSKTW%U?(?=XZ^^7#&6,* K,Y/.&LT[O\T&_C.#YTS]I7GKJXT_5.
M+[K=]BE>"5]][/3?P3>MJTZOTWWK77SHPQWZ[SH]&LW[=K>/%W3AJ:UNKT4_
M5O?IM]]?GK?Z[3-^V1W:0EMEN3$OL<3C7ZWXQ#5X\K*1AA*%>V%T9RLR$D:,
M$6ON5](5%BEZ"(VTB)GET!;708VU[^PA_1,LR;)I VB]%,7GXI&BMQ3J-#AK
M:M50BOT[D]#\*=6,YWLC?XA-T2'>$!ESJ5%:_V%O!X]Z#:H%]XM._AS,@I%N
M=R<6!HCQ^U@W('M3L:K-%&Z*!Z!G=P>7F*S_AX/>@3ZOK2#:O<[;+M(E*)E7
M@9S,"P^N#Y0+=7M[ /!=<,\#=3OZ)%26$G[B!_$@I,_#Q5!=GS=3D.5WO7H+
MR1.1W[B<<2"0Q@Y([ NFN#$CQTG.T-WYB>Z!L*]]&R+8K1)V=!WA^:"_>LD$
MY&<"JB^9@%WGGY4&?1=B"VB2=A=O^/.\H!?W)QK#BPYZK!\.-:VW39DBRPX'
MUTN,0:Q#7!GG+1WV?W9)48Q)*H7) 18I-H;\$@Y:09P/.8;0HR4W0B+-L:TB
MK>:2!C_33G#J5Q3I$9!^5K[B%W8CI'[(GM0<V K)M<D,&YTH/]68P>Z2'%3V
MSNL$PJ^;]4QW,?%;9<V PDQ9"5!"ID>?WC,%@0.-7T#V!)W66(85SPDP7.<F
M1%1<PE+9G(23@*!(J0#TAFU'!8D)N@ZFLS^:2Y=#K9-1;EF:=MS4&<^E*!3X
MSRN$7^?U:JO(0G$F5D$8NYX-??+S2;CHD*2I'#4;?=ZH:;06-8)OS0/0_Q;A
M%Y%ZDV!I-O/ O])>.;C44RY=DR&N:3K\RL6V&_?\2A#*])OACN=7RRM2$9RC
M2<9?BQ*3I,76)S!4W0I#X0[95&8I9^P8OY!<7'JM\O*5>*D@TO /^'7BR',5
MX.TNMOE6W;QJFU/1CW,BMJ9WVG$N69?>]&U#K?ARRC$CP8D62V^3*N.N 49)
MA(Y$!:SKLD#=(W$L:XP:2D?G DZY((#&IO\14TIHV&+5T8QQ7ZS1;^,V/U'V
M(7MQPBEZZTJ ID='P<*],*B.C1C"9"-$:8PE[I,0VIAXJ^ER,-OC1?7I"^Y,
M^0S[,R::-(,"P]D=]'/V?Q+=<[+\*J?T*@@1ML\ VN3"0U!('8(')MG'(8Q4
MD2E%B*#ZGN(JU@TS!0 :MD#["X3&JZ\7D9C4JM&VP0.W7N21&G1&J71VSC-=
MNYA_?U1->PX$USF$ J^9#Q2]?WM5?H5_SZ#_BO\F\QG_&05_>_5_Y6%8/SJN
M!N71X: ^\(^;HV:S,1C51F%8:]:#QBO'H1CY:MG=_>C]5S^:* $"Q,A5K-37
M?VE? AT.<G7RK': K8=^JA\]_2_6%"PK>+>,$>^Z#O+?\-;SG]U/X+- #_H+
M -VJA:WOKSRQGU[!_96(IG][57V5^3%/<QLS";!>YOXL5+[J,$%PD[1'I!?"
M(DA]J#Y*C^RQQEHIUQK>J3\9S"-U"'F]A=)<RC#H+:-%Z%6.6\]QS&:X)>]]
MRRM7*_7*(PY3+\6&6HFY0RX:9E]IQ]F-4FP_;CRZO <?;_W@O6JENN\UCJNO
M*Y5F\SF*IHT1JEW+11U*\_#VX#=E=:G3\N\A;M/%'Q!T>HY":BTXX;]K.;50
M3MXO)*<G%8VN1GBD-SV] 42!-Y&RY8< )GQ!K##W?V5QI/Z 9^J*\_ZAS8&/
M9!I1,BF&?+(->(,3(9(]4]/%FTWQ[._:BFCX1T?'HV&CZH_">L6O-&N-8# *
MFW7UWV 8'#^A%3&_'NR52Q[\=_])3(FWZCB>#L+Y-?A=RWET7?(N#UK/TI*H
MU6I>[Z!]X%7_.UG."F\'HH9[>F-EXK_6\=>*,WO)1*U9#$L#,9ZZV\]>"U/
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M'S"=X7TJ_*]=^(_.2QA$PD_1?,VO=19!GDS4"N0K\':>C+6N7N*P=0_1#YC
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M,=%1^\\7P5]=&08Y?FYR6">925%7+X)52I<CV=";%82YK,PT/HZ:0C,[G+
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MLCN-Q323=HI24&2"*RD:&,PFW7^L+7ZES_V>A)5RMPP1"7RX%6L@B"(.Z$9
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M '8N8VT(; X,)O G8^6;Q008[ PH-]&J>>GC,VRSL 8ZU2W@*:78J SUFF7
MT6);&4S/2;AYSP*!YQ('N9\R56H<.%,J:0"$!I%XBW5!7"I)DL2DBI883%V#
MDFWLN@2/M2,[LO:E7+W#\Y[ U@DWQ-BR:"B,BU3GJ/9!"QZ&&IN %BVWGN)6
M8/IS\$J1%=BI:5Z]+,["9?0NF,7'&<HDE9)6-9>4F[QF0FRE"<II2&]$I(.V
M_/JZTB]FH0#A4'/4F]H]I%.46$/FHXAPGY5[SY5!7..9"I',EZ)Q'I5J3)_L
MFIMVZ]O 7P'/QKJSE R=>*IHA8J<<"L:2-Z)D^*71N$-#D.F%3$P(V49MK*6
M 9!6Y#!AOI<!(OFU9,.2_*TJCK+Q$"OYV-+M9X@6[6#FBL03A_#Y(A45%YF5
M]LZ_R=*=,@R8!6QT[0 9SSP]0P*/RS TQ&6=-)GA">)[)_=+867I]QU)G\DL
M0UF%I,0"DX)5'Y!9<6Z]"RR'U+O.21:QE9&$(V/JHU)>+CD_DP@G-_H+XH;B
M4M#GB[)#HE;+-$C.X8PL !W7ZZ/L8F0;H 4*&'1HZ*),I$[ZE$Z8S(KT!LWP
MW*YKF:W<EE/,ZT[W<&62I)XX"^ZD7E%HE/KN*<Y2$4II2R;#;H&(@"YU(CPS
MR9*DEJ5?AA7$@OQ<84-/Z+URXU$97,"6.G"1K3B!_;**&9!''X%$*G#G]S6G
M%HUM*+ZU:.# B18XOF:)]#1B_YY,"*J5((_FVT>WZ5S7/G-.V, :;^BBGL]6
M8Z?LJEFO+22$XFW5^TQ+T[$)0,VLT0>J[(*IL2'((T+G3YB5CKAEG2.)6=#8
MKYLR/&.,W-$,43)EMCEBW2!X?WF%>.^MLZ^6_&'V1QFCWC)XG DN9.7,J)-[
MRRAL5H]VPR>"]4IW6#?ATMCZ%(DB4UM;V=JTMB2PMK+77#-]?2EF]VSD:R/H
M%S.A^^M*YW7A0-1WRQ84,2L%L> ,K,;<7ZX"=3^MR>IJM)C:5*Z+1 W*WFD@
M53SONBTOU<L0-A;#(53 G'C#AZ0U43TLVGBT->Q5GLD+@4/I/N/BVT!(/3JF
M=M\4TJDTO&4\<X,HS *TDA':  YD:U>SFL(]A:)9-8<H1O<0[=+>A4=6-%^2
MSM[MOR2=/;7]\<1%&N=N7R@+Z+_>8^M:(-6[7\=N\<:[(*0JT&W+'@Z.N[%Q
MNZ,(?L;%!:GY B9>W"01.7$D)V\UNFU++)X70(R+;0,E#G7PO0(1A!:+ M1A
M%XBE4VL[BQ&&FG:G588KJ/F>W]!JP-E'.2/C/ZL9R.IR2GY!0J'&L@EX-T2\
M18*9DHUC78]423NI&SPAY,=4I^.H#K,FA%?W+030]E,)03Z0F+O >D!A4V:9
M6B^I8YG0FR^1-3A)>5P@W&TTE<B._H R5&9L:K.;449L*]3AA$PDC!99$VP-
M-6N%39>IB0!KC@@4=A+B.?6ZTJO6+H/FP%05#I,IUL[=KNX/WH&6<2#7H10D
MDS"6OFHU'9ZEF#DN#V@R_CB$2;=4#=/HQ:K?LQD4K_'$P]A"%*?X'I(90R03
MK!52.7K;@U EB5#BO$1 RV\1:Z4</KG+!,TMX)GI+;#@C]3Z%3"CX6QN<7AY
M_/)#>2IEL$S4_JRFSS6[U5# %(M14H\:K6ZD'9HQC'F@PG\SKF!M0]2ZSV+9
MG5/AKFV]&E"3Q3:([1+&OS>-J$KSMW?>GI<34["NKN[VO>@L^%B0.D.%(:,1
M(WUM3F"8J,C*G%#% 8VI9IU55K(<V>HWY7C-$L+83\/J$QR![;#$@3*=+!%>
ML1N1@Y4LQM8BYG1UEFB$5=WN!/4',M6G_39]I!@DB)ZWP!:T'#NW8MF63K:4
M>%KGX+-Z/,$_J>Z>I/)E*9T5&8XLZROMN?)U8.?V%*.$0E*O-D<E<A:9FPAB
MK%>.::$B'6NIB2N0@2YY->G<?(GO%V$S,^"!^C[,HV-[\8H)#LGDQ;:ALK80
MSTOE"4^=A$;Y%$T[F$C,AJ<ZI@])%"6WS)%+*0H:4Y5K"'7Z3FLVY?3):YDF
M(TYC2[BP"D5MUGC&33RDN7J3H:[#E#-:*0$:4:<RIDM&7PRY<YN;:\0).J8J
MLK)N#?Z%6J?-H%1XT H'EE3'9@XKW=V^K4H0DM4,K=UBF Z$I+Z?Z"*%^ZP0
M2BH/E>,8TJACX3,D:[U*C:Z925[18)L9"O?!A;N(&J@G]2QK2K)2PEKNRD2X
MGD$;SC+YZFQ2XC_VT56)2)E6\-$)-4(,!YB5I6L4\4"E^TXQ.*N1(J:V9U;S
MBU+6O!2C7-JA>A#!J4><LRL;O@>-WL!4:$?SRM##$[=NL^C!=I!GE?PT??ZN
MV>GY@6H,F>C,=DYVX)XG\FBE72D-J#LR=67'-W +)8TSW2=IW>%BH<2OK/FJ
MK&>PHB#E9-'(OUV9RO;]5:YL/SH[O;HX>?]Y=:K9KQQY9CN9%&=EQUV3@$LH
M)LC\C+*F2V6%=6:7SAO0*>=C_ULX+JQL.B<>59?NIR)/ED*C.GTY#5F=F(WQ
M'^8+548V>E\X/S7&WJHPP"Q,Q%$11JR3#%._P!;T,66[E[P5:ZPIF0UHR!!H
MMPD%HR[3?=U(-W0[()Q%);+'>C/9 7/FC1D,MQ(@8[$UO#6,RWFFQ'&>^T2:
MO=D .CNF)^304APG.C9FXFLZ2J9EJ_)]R&=J)!(5(YN!=W,/J('OS" /[BYL
MO65*VX=SR8O>^=G%U:77/3WVCD\NCSZ>77Z^Z'F?3X][%X14>=D[^GQQ<G72
M@\\<7:T&(_U"GBWO)H1/,6NCB$$C.*Z5Y$M*YP66CK1W=B@9M8C8C&Q*?U%.
M&MDG3^DE7'UB[I!5AJ)81N^(C194&FQH869]E010O$%./9M;QR07-2GZ$>C0
MRKWA8" NKSA-[5!]+:4U*Q8PH$CE+C\M]YO,$E-$(<LQ,B]*\-A*]=[);=S4
MV[JELH,;8/ M[/LW+Q'E>T24#UXBRD]MWSTQ^BYW^P#E@OS@DMDXN6^*R[8J
MD*M)IC#6T+(F?@HW.@E4:JI*<U+,Y>VJV-Q/G&6,%:Q.4:H$DIH0KZ/<1Y)-
M&C'7=6A*9TU)G#2*.Q6-<Q(^L\1AU@90&5.3,ML>EI4F]%#V#*@!#4ZG_$SC
M_-'<,:UVI #'1#C9)(<LA8R+\8>K1TY/G#12"M:9!"V53"(!/KGG'/EHG-0^
MZ9 VA4^E>A'2>4)NK(#QCBA4+6-DZ#A)->89.O'";! E&;J]Z\]U;2!UC@4(
M516DZ[[K9-LE64X&"UG=L0P9_ZL "UFDI$#@E,H71%<,$7&Z5\I0KJ%9N"+4
M#KU2>V,W5M*- TH=O:1?J185%YU,LS1&MKYJ4PZUHENG+I(1N2IW9JEN\%)#
MN'M8(*8/A/)GFI0F*JEPZ:49Z]@^3B&#-G6GW)QS67O@<ROM97B)[J$B(IF7
MS6DAF8YYXD]8D$E>*D&P/ZI]M6IO";,J)#I*%0WV2J6.=KE#HD7M:C/8:X"V
M$7X=_ZUTDHEM9Y.UHR7$:><+]@C:$F&82 NOGB^0<E?,WM<&+U4=XC]^RHF'
MN*#VC9?>1%9$>>O<_ Z*E^"BK<,F(U-Q:-=GQ'%+?9"*R[JV%W<AEUNTQLX^
MNZQ7QJC1'#;90[7;+'-AUDD<N/ %RUGU,_9/7%4,9!:*$G)+HR*AJQ<,()!$
M.6[(6 13G;&!MA1755'Z-:O5<5"2D4[X[4 2/3S))4<KRZ,$W112<0!1NJ(>
MF@?!WN3L6BXY.3,AOGIX8CDQ(HH0#RTPBC&G#TSP#6QVFU+ !268'_-Q_E[$
M XFXJEC3M7\C ^@(,,0;D+!^(/TN?"^G+5,;I';(!ENRMDW'MVGOS ZPIB/W
M\.XNR'EOU]O[=Z4AY4R(Q'!ISLS#S;OC7+HRM'C7O;P\^?GT4^_TJ@PH[%V<
M_/S+U:7K0'SD#7%P*"NG\007_Q$Z:%=:X6!R+4S=*Z'$*( 3F07C**RF.WIF
M<FSN7@DT*T%VRA4B"@)/L1G@Z&.1CO"#J4C2D1^'_Y8:".&V@]9 T7Y6-I(H
M#.2[B/X4#V0=EU5K>"OA,>NL4 H[4,U**;^/V-?4@?WGA'GF#V;B;G%3@%N+
MW@NYY52IX_;W04YNG0D*3WD"5F9+URD%NUO)N@5T3=$XF#C:T2@PRL); 5:(
M<C>@OX.<I1&.0%7"_?Q[DET7OG<YN!9@AXB(,>IDF9<OT1=X20+,IP(Y,JZA
MA*\"6]1'#YN2VT9(Z>0U(Z3T)BBQ_3!FMC(Q]O;6,P"G?7A H L\_WAAOO]<
M%;/3Q,C^&J0MI9<9()5;7P4YZ<IR'J *[0:2BU!&+Z._^:1/U393M;G/!+T1
M@<.E.( ?4@Z[\9399E^I7MYV"&YZE\8#1R/5/4PW<4#$DT4V@GP_:C,,(^K;
M)2UL_'&K<N07M%GH6]>[98 A&5"(M[3D5:&!*7UQYL#J%*8ZQX?0@T1,59$J
MM9'8.CTG)70#1$(#SOW!@*\0K@E#DF)G1HPER>)DF7"4*GV\EH^[,HDRT3!A
MF39&I^++836@3&ED2RDW4D?9LE1T*E<@\^)>@/GO$]$Z?(EH/;D$;/\0$O#3
MR>51[^/'[FGO[/-3B+M5CRQV578F]?\FS9IU2)^ ;"KY2@T5]9CC*VZ4[JYR
MRV_9O>4,C75V,"1(/[AG,_.0Y )/AB6S@E*<*+5U&"%6,)4P&%]G2R;ETZ-%
MI+K!L#/SEB3>&$&Z>9+E<AX+HJ<QV\%UI+JF(*+*D2^$LEO\+"1=NVY^]O1,
MXI;.U.*8 (&*P9;Q.<SLUYFY:"?T_"3YRJH_;[=V+;J^O)6Y*T\<\>W&JI[6
M<<.S0F  2IWBK60\+F+MV35AW]1*M>0+-\+.Z%8 V.J+YFJ!:/CU':N/LNQ#
MSGPT-XW*764W>XE/]T9N!*J0=L/ %B?I&QR["5T.3.21@),UG\YDE''H#RC_
MBBD:C'X''WI-UQ(Y_>%Q74B$"IH1EC@6&#&$O<+T(74YTD2] I1*6E@@$R&P
MV5I,P3VE@F825H9TO74)\8N3K]7\V4H(!/46E&697NQSU(C\WX-D% -]P&EA
MA3SIB7*',)DS92!"!P ):V$Q>.F4- <!0OP8+""MX<I+KSF.77.DOD6]/6!+
MS0N>[%0N]SPF[8W3@&6YJT-R*B7VS:-<\JK_[Q[VW\FP!)-4DR;FZF[R@7O;
M9=67O=\#$479Q$='U5]?;;VBWR<8$I2_LXI'/X;!7U_]>T=L]0^&^X<';='9
M$;O] ['?WN_L]+?VQ>ZPW=]^=6__:)UFB5AF_B2#SZB?)+.4FXMKJRB:KGIK
M_XRK3M^YK^!K@9KT#4:7X ZI\<&4 ",@36YAB^*_OFJ_PF?QSYU7E8&:B8#G
M>??C[L&]BWVD\M2?B +FEGDG\:#BF%8$F0>E%^&E\H)7; O:6]N[WI$_[J=A
M, (QG@-S![9Z681@9;8/NG^@K="[T/(^=;VM3GNG_8BK5_>Q ]>Q=B>^PXJO
M0+!-KD$FO5EXH75K.#AXPC6L==J==6_WH+/1;A\>_N 'UMM ";S"IP4:0RIN
M-W_W!U]!J_N;( :<?]L$5>$'/[IN3@@D2;S"I]>ET_/^SJ?WI ?F1G979PN/
MKC$;X@-'+_W(.V,XW/OOI1W>)IWS_KD)CZ]?R\(<2K[$^MYR A&:LGF8%Z![
M&->$-'!T>5F6K3^V6DZZ^):_[7<&8LOO#_=W@KV#@]WAWL[A<%_L!3O^=O_P
M11>?23!WIXZ?0?>,P80<H5>H2,-1RSO?[*ZB-OZ 3=C>WO8N-WN;7N>GK)@T
M3A0?AK/UHC 6&RHPT'9&S,;8IRF%03&/%T9[YW5O1%P(I=_O[&QM_;%V]U,(
MGVYY'^ 6A8'O;6^WMU=%R7_ JI^3GO^ 9:QM;^V"JK]_N+&U>[ JJOX#UOM!
MN=9^A&,[W&MO[/XACNW9&&D/6(,?Y?!6\+=1CG@EJV.=/6#)S\E >\ RCM%"
M^[3I=>D$6UXO^]<#-*CO95U4TPH>Y+U7.8_?Q4YH=_;:.]L'6YW#8'^G,]P^
M'.YN=8;M_<.!W_8[6^T7.V&9!O1'[/H5Q8CO]-4[\B<A@D5_*!#1^./'HQ74
M9N^[$:"\>Z<48_^"5*IU^O8JJO0/<*<,_%'2\DX^>GM;>[L[*R*G_L@>^^UV
M9^.@T]DXW'Y4Z_,Y'-=STN"7<%RK8BK_8<,KOV>Z9.-OT60P!+&8H?;^^O=!
M,A'.2S_X43XG;?Z^:\ R'*L(Y[53I_,'T>D?,6*PX-J69RCT=W:W]W>#'=%I
M'^ST@WU?B,&A$%L[.WO^GG]P\&(H+//V'"=I)J;>?_GCR5OORW68Q_#;QX_G
M?R#M>+<-MD&6>[N/$DO@7*&GE"-/N+7X[F])^K7EG?Z&]ZZ]*H[-/[+EP;E"
M.^W=C<-.^T<W%7\$VX,/['!W>V._\V)]//?3 DTI"P?)IA_GP"BF?PM( K\8
M&RMQ>%T^-._OF]XG/L?G%#MXJ51]AW[=FKJ)&1OT!R]5O?L=0(R4W$;ADZ4N
M6.CR&MXLU[JHUV74R5=L0%?(\2BJZT0FR^D&X20DB'LJOT$81"SYXPX5_6FY
MHP]78V$9NF]WI[-[S2&^D?#6MMVZHDQ"B*@V.81FAH/)3L!<HT/0B*K>YXM!
M&W$*I%3CT+7NNIR/+'0RBU$#\JQU59HJ2G-:7)FJH):W]GY]\7HK?JK9!*RS
M$@93S)S/&/8*-D+7@7G^8$ 8];(-B6H@@UAR+0)G:%EKJ9RS&88)@CO*:,#1
MENP Z(6(WZ5*&V$',SSDD<&Y=PK-L"CL:-UTN")T@$7+ONP]D/5?NN5 *OI%
MSGX)@4/'TA4B*^G,-ZQ^L$[IG'J=<2SN7(I&. T#+//T\='<QC.B'BYKX;J$
MX-0E<7X?1FJINE<8*)H^)O#_#P'1>D6]C[C%&+64T?6TA/^!OQP+>!EQEDN]
M'#S99I<[+F99P07, SQ,>2FX7]F-*+5,LX%/$<@HRY/!5R[-UB7271B4KSE!
M-U+=7VET\MC)$N26=P.'%1!NFXW1P:B1(*DFV'$TKP<AT?3."[*[DE)9053=
M&'L;X/63* KC)+1PYF3C/(G\*/N;#*X3Z4V$ 67702KX5B]94"D2^7]-X^B5
MCD4]TNT:\'N1AED0<EDV0R+*!BK<^LC"-[8["*CU<:-!:P@'%LIZO+U^-1-U
M=#VL'94BB3&TPC05-\F ,!BSHC\.<]VN4GP;1"!J@$;LYZIY$?0O5X<*H X_
MHD9=2#(@7KA*OGY76D!DP*4)F?<H2;YR)P!:?4#=V_3R<<E!F$W0\6L@R[#$
MWT&#5&"0A-4C^YW:FV!C>Z%H$.-)1))&;H'$'RZH:I8;5S&SK]DB$G2R9Y1$
M=40/-;<[!JV>V"*!#H8@%NOZ6[>8W*A5HD))#GD44P9M@VGCSI0/0.,:TIY+
M #;&,,4'VZNO;<H=$KXG(N+PA!'5,XE!YK-H3-)BS)B*LMT>911K"=>\.!PX
M''-=\F(TQQM:D5N66U^!B5'].Z%#RM?[@O&,TAO9LT9MRF)[@+!T/H,LJ=B#
MZJXI$<PER% NB9/51%WYK' ?X--A7@\19%&)=4)RA:JUKXYMC!1,?E9@P0@=
M1<-VJ$:0$A5([O1I@CV-1J8-F[T'I8YL5N4^00*K#;SUIQ8$$D%]PO[JA\M/
M@8A"D(AR_R8+1(/ E6:@2^EYA#&)!SR<(I;R@=0:^2B;]%NJ!Z62**5O<:]'
M"R616+S#"Y"8K2^7OBIY&X,)!HJU.Q,GM@9GZ5[)=(&1YVV)7'!56FPN0Z%P
MK= ^B'1T1W6/?O'.NQ=7OWF_]"YZ[W_S3BXN>K^>'77??_S-^](]^15; IW^
MQ@!OWLF5]ZD+'^W^VFM1-Z'NSQ<]^,3IV95W=>9=]/[OY][E%;SE_?WSQ6_>
MU<5)]Z/WX8R;#'6/__[Y^.2( >/./M"PQR>7YY^O>O1P;D<$'SXY]8[.3D][
M1_1)?.O+R=4O^$[WXN3RY/1G[^PS0=!=_7)RR5-@4+H+&O/JHGMZV:4ON\X+
M;!;7^W3^L7O5.Y;+-5@DCX!6\-P1T.^CDE;8&Y+]>9&";0<JC'[+WGB+PY%6
M =8S:*R^&66<2*VQ!!97"Y4CY:)LKRL9MIR(S0NQWE]0#Y(X89C14 'BR.;+
MA*62@F[ C9929N$Y]9'*&F?EHG%2NQ,+" ?-JJ' 7J(PX1KNJR<:QF:B"^XI
MK!VEI$#L;4(71[O?:KZ)WY3]5GQ")FE>Q#VW=E5NR9.W1W79>D;&2JP:7.>F
M$9F4-S:AE [*QYS7DC+H-%:Q>A4>$EA42.H)"NLDE6CA6DHSG&O&H\H&RPZ2
M$Y"HZ=E8)1*D=@5D9<.!FV:PN=6^6VJUU34C)A7#YI8T=2,=)?41[#C)450Q
M6I9\Y&FL#$D.GYHDT8+RF2N$%=QH9)-#MGG9!AB4K6AB:^QDBB/9%T6K6:Q
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M45(@S,_JIY]>]Y-@2C^@KQE^^/]02P,$%     @ R#N+5HDC<Z]' P  .0\
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M<*Y)G+/XV*\(4*Y F>2P@#?85?*:]1>!U^>4X->Y]EX ETFRP;1Q&6CE<#$
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MM=_\>I&UNR$'$I[\W0OK=#_D2*3- +DI]J?P<(FIX)ROJ/I5SWP4SHM1Z^3
MP).^2S$MHCM2:+DA=[QN6$824@JO?D<EY@29EV5N@#["6P#P5&XMH^WH;AFO
M]87<Y[KB6-H2TP17_Z"0_];AE[-9XSZY':@6R@>$IWOGLEKT]^71/H#<YS+X
MGQ?%"O/.;G#"[9ZPP,$[HZW$_?QAR:9=\MQ>VG'86,*)V"#_=KZ-R!?Y-^U/
M_P-02P$"% ,4    " #(.XM64]Q%>]0=  !NI@  $P              @ $
M    8G)H8S$P,#4P.#$R7SAK+FAT;5!+ 0(4 Q0    ( ,@[BU8I::U#B[$
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3!@     &  8 D $  & H 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
